WO2023138695A1 - 一种组织蛋白酶k抑制剂与其制备方法及其应用 - Google Patents

一种组织蛋白酶k抑制剂与其制备方法及其应用 Download PDF

Info

Publication number
WO2023138695A1
WO2023138695A1 PCT/CN2023/073612 CN2023073612W WO2023138695A1 WO 2023138695 A1 WO2023138695 A1 WO 2023138695A1 CN 2023073612 W CN2023073612 W CN 2023073612W WO 2023138695 A1 WO2023138695 A1 WO 2023138695A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
carbonitrile
pyrimidine
methyl
compound
Prior art date
Application number
PCT/CN2023/073612
Other languages
English (en)
French (fr)
Inventor
王进欣
张贵民
王可
姚景春
潘丽红
Original Assignee
山东新时代药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202210098531.3A external-priority patent/CN116514804A/zh
Priority claimed from CN202210156862.8A external-priority patent/CN116655540A/zh
Application filed by 山东新时代药业有限公司 filed Critical 山东新时代药业有限公司
Publication of WO2023138695A1 publication Critical patent/WO2023138695A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D247/00—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
    • C07D247/02—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00 having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to the field of medicinal chemistry, in particular to compounds for inhibiting the activity of cathepsin K kinase, their preparation methods and their application in diseases related to or characterized by cathepsin K activity, such as osteoporosis.
  • Osteoporosis referred to as osteoporosis for short, is a metabolic disorder that reduces bone mass and bone density throughout the body, leading to an increased risk of fracture in patients.
  • the pathogenesis of osteoporosis is caused by the imbalance of bone resorption mediated by osteoclasts and bone formation mediated by osteoblasts.
  • commonly used drugs for the treatment of osteoporosis in the market include bone resorption inhibitors such as bisphosphonates and bone formation accelerators, but these two drugs have certain defects. Long-term use of bone resorption inhibitors will affect the differentiation and proliferation of bone cells, further leading to the occurrence of "low bone turnover state"; bone formation accelerators will increase the probability of patients suffering from osteosarcoma.
  • Cathepsin K (Cat K), a cysteine protease belonging to the papain family, exists in abundance in osteoclasts and has become a new target for osteoporosis treatment.
  • the human bone matrix is composed of 25% water, 25% organic matrix and 50% mineral matrix, and 90% of the organic matter is type I collagen.
  • the degradation of type I collagen is the key process of osteoclast-mediated bone resorption, and Cat K plays a leading role in the degradation of type I collagen.
  • Cat K inhibitors inhibit the resorption of mature osteoclasts by blocking the degradation of matrix collagen.
  • the coupled signaling of osteocytes remains intact, thereby avoiding the occurrence of a "low bone turnover state”.
  • Cat K plays an important role in the pathogenesis of thyroid disease, cardiovascular disease and gum disease.
  • Cat K Diseases characterized by abnormal expression or activation of Cat K include thyroid disease, cardiovascular disease, bone disease and gum disease, specifically hyperthyroidism, atherosclerosis, cardiac hypertrophy, heart failure, osteoporosis, osteoarthritis, rheumatoid arthritis, gingivitis and periodontitis.
  • pathological conditions such as coronary atherosclerosis can cause increased secretion of Cat K from endothelial cells.
  • Cat K is closely related to the occurrence and development of cardiac hypertrophy and heart failure.
  • Garg et al. Garg G, Pradeep AR, Thorat MK, et al. Effect of nonsurgical periodontal therapy on crevicular fluid levels of Cathepsin K in periodontitis.
  • Cat B and Cat K both belong to cysteine proteases
  • Cat L is an eosinophilic proteolytic enzyme, and the source of Cat L is difficult
  • a cyano-substituted pyrimidine compound designed and synthesized by the present invention was tested for its activity against K, B and S, and it was found to have good selectivity, so as to be used in the treatment of diseases related to or characterized by Cat K activity.
  • the invention provides a novel ketone compound and/or nitrile compound acting on Cat K and a pharmaceutically acceptable salt thereof, as well as a preparation method and application thereof.
  • the invention provides a kind of nitrile compound, and its general structural formula is as follows:
  • X is C or N
  • R is selected from H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C3-C10 cycloalkyl; wherein, the substituent is selected from halogen, amino, cyano, hydroxyl, aldehyde, carboxyl, sulfone;
  • R* is selected from halogen or C1-6 alkyl
  • Y is a ring group, located at any position of the connected aromatic ring, connected to the aromatic ring through 1 or 2 carbon atoms, optionally C3-10 cycloalkyl, C6-12 aromatic ring, C5-12 heterocyclic ring;
  • the C6-12 aromatic ring includes a C6-12 aromatic ring and a C6-12 heteroaromatic ring; wherein the C6-12 heteroaromatic ring contains at least one heteroatom; wherein the C5-12 heterocyclic ring is a saturated heterocyclic ring or an unsaturated heterocyclic ring, and the heterocyclic ring contains 1-3 heteroatoms; wherein the heteroatom is optionally O, N or S;
  • e is 0 or 1; when e is 0, R 5 is directly connected to any position of the aromatic ring;
  • R 5 is selected from H, halogen, amino, cyano, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, substituted or unsubstituted C3-10 heterocycloalkyl, -S(O) 2 R 2 , -C(O)R 2 , -NR 3 R 4 , -C(O)NHR 7 , -SR 6 , -OR 6 ;
  • the substituent of the C3-10 heterocycloalkyl group is selected from hydroxyl group and C1-10 alkyl group;
  • the C1-10 alkyl can be further substituted by hydroxyl, -C(O)R 2 ;
  • the R is selected from H, amino, halogen, substituted or unsubstituted C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl or C3-8 heterocycloalkyl; wherein, the substituent of the C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl or C3-8 heterocycloalkyl is C1-6 alkyl.
  • said R 3 , R 4 are independently selected from H, -C(O)R 8 ; or R 3 , R 4 and their connected N together form a 4-8-membered ring containing at least one N; wherein, said R 8 is selected from C1-6 alkyl substituted by piperazinyl or methylpiperazine
  • R 6 is selected from C1-6 alkyl
  • said R 7 is selected from C1-6 alkyl, wherein C1-6 alkyl can be further replaced by -C (O) R 9 ; wherein R 9 is selected from piperazinyl or methylpiperazinyl;
  • the C3-10 heterocycloalkyl or C3-8 heterocycloalkyl contains 1-3 heteroatoms, and the heteroatoms are optionally O, N or S;
  • halogen is monosubstituted or polysubstituted, selected from F, Cl, Br, I.
  • R is selected from H, substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted C3-C10 cycloalkyl; wherein, the substituent is selected from halogen, amino, cyano, hydroxyl, aldehyde, carboxyl, sulfone;
  • Y is a ring group, located at any position of the connected aromatic ring, optionally C3-10 cycloalkyl, C6-12 aromatic ring, C5-12 heterocyclic ring;
  • the C6-12 aromatic ring includes a C6-12 aromatic ring and a C6-12 heteroaromatic ring; wherein the C6-12 heteroaromatic ring contains at least one heteroatom; wherein the C5-12 heterocyclic ring is a saturated heterocyclic ring or an unsaturated heterocyclic ring, and the heterocyclic ring contains 1-3 heteroatoms; wherein the heteroatom is optionally O, N or S;
  • R 5 is selected from H, halogen, amino, cyano, C1-10 alkyl, C1-10 alkoxy, C3-10 cycloalkyl, -S(O) 2 R 2 , -C(O)R 2 , -NR 3 R 4 , -SR 6 , -OR 6 ; wherein, the R 2 is selected from H, amino, halogen, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl; wherein, the R 3 , R 4 and their connected N together form a 4-8 membered ring containing at least one N; wherein the R 6 is selected from C1-6 alkyl;
  • halogen is monosubstituted or polysubstituted, selected from F, Cl, Br, I.
  • X is C
  • R 1 is selected from C1-6 alkyl, C4-C8 cycloalkyl
  • Y is a ring group, located at the para-position of the aromatic ring, optionally C4-8 cycloalkyl, C6-10 aromatic ring, C5-10 heterocyclic ring;
  • the C6-10 aromatic ring includes a C6-10 aromatic ring and a C6-10 heteroaromatic ring; wherein the C6-10 heteroaromatic ring contains at least one heteroatom; wherein the C5-10 heterocyclic ring is a saturated heterocyclic ring or an unsaturated heterocyclic ring, and the heterocyclic ring contains 1-3 heteroatoms; wherein the heteroatom is optionally O, N or S;
  • R 5 is selected from H, halogen, amino, cyano, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl, -S(O) 2 R 2 , -C(O)R 2 , -NR 3 R 4 , -SR 6 , -OR 6 ; wherein, the R 2 is selected from H, amino, halogen, C1-6 alkyl, C1-6 alkoxy, C3-8 cycloalkyl; wherein, the R 3 , R 4 and their connected N together form a 5-8 membered ring containing at least one N; wherein said R 6 is selected from C1-6 alkyl.
  • halogen is monosubstituted or polysubstituted, selected from F, Cl, Br.
  • X is C
  • R 1 is selected from C1-6 alkyl, C5-8 cycloalkyl
  • Y is a ring group, located at the para position of the aromatic ring, optionally C5-8 cycloalkyl, C6-8 aromatic ring, C5-8 heterocyclic ring;
  • the C6-8 aromatic ring includes a C6-8 aromatic ring and a C6-8 heteroaromatic ring; wherein the C6-8 heteroaryl The ring contains at least one heteroatom; wherein the C5-8 heterocycle is a saturated heterocycle or an unsaturated heterocycle, and the heterocycle contains 1-3 heteroatoms; wherein the heteroatom is optionally O, N or S;
  • R 5 is selected from H, halogen, amino, cyano, C1-3 alkyl, C1-3 alkoxy, -S(O) 2 R 2 , -C(O)R 2 , -NR 3 R 4 , -SR 6 , -OR 6 ; wherein, said R 2 is selected from amino, halogen, C1-3 alkyl; wherein, said R 3 , R 4 and their connected N together form a 5-8 membered ring containing at least one N; wherein said R 6 is selected from C1-3 alkyl.
  • halogen is monosubstituted or polysubstituted, selected from F, Cl, Br.
  • R is selected from neopentyl, cyclohexyl.
  • Y is selected from the following groups: Phenyl, pyridyl, thienyl, thiazolyl.
  • Y is selected from Phenyl, thiazolyl.
  • R is selected from H, F, Cl, cyano, methyl, methylthio, methoxy, methylsulfonyl, methylcarbonyl, methylpiperazinyl.
  • R is selected from methyl, methylpiperazinyl.
  • the invention provides a ketone cathepsin K inhibitor, the general structural formula of which is as follows:
  • R 1 and R 2 are each independently selected from H, halogen, cyano, amino, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, and the substituted C1-6 alkyl or substituted C1-6 alkoxy is further substituted by at least one halogen or hydroxyl;
  • t is a chemical bond, optional at least one of.
  • R 1 and R 2 are each independently selected from H, halogen, C1-3 alkyl, C1-3 alkoxy, and the C1-3 alkyl or C1-3 alkoxy is further substituted by at least one halogen.
  • R 1 and R 2 are each independently selected from H, halogen, C1-3 alkyl, C1-3 alkoxy, and the C1-3 alkyl or C1-3 alkoxy is further substituted by at least one F.
  • the C1-3 alkyl group is methyl, ethyl, propyl or isopropyl.
  • the C1-3 alkoxy group is methoxy, ethoxy, propoxy, isopropoxy, monofluoromethoxy, difluoromethoxy or trifluoromethoxy.
  • the C1-3 alkoxy group is methoxy group or trifluoromethyl group.
  • the C1-3 alkoxy group is trifluoromethyl
  • R 1 and R 2 are each independently selected from H, F, Cl, Br, methoxy, and trifluoromethoxy.
  • R 1 and R 2 are each independently selected from H and F.
  • the halogen is selected from F, Cl, Br, I.
  • Another object of the present invention is to provide the preparation method of above-mentioned compound and pharmaceutically acceptable salt thereof, the preparation method of formula I comprises the following steps:
  • R 1 , R 5 , X, Y are as defined above;
  • L is halogen, and halogen is selected from F, Cl, Br;
  • alkali is an inorganic alkali, at least one selected from cesium carbonate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, ammonia, sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide;
  • the solvent is selected from at least one of water, methanol, ethanol, glycerin, propylene glycol, formamide, acetonitrile, n-butanol, dioxane, methylene chloride, chloroform, acetone, dimethyl sulfoxide, dimethylformamide, ethyl acetate or tetrahydrofuran;
  • Reaction conditions heating reaction in alkaline solvent
  • heating temperature is 40-100°C.
  • the preparation method of formula II comprises the following steps:
  • Step 1) Compound P1 reacts with (3aR,7aS)-hexahydroisobenzofuran-1,3-dione to generate compound P2; reaction conditions: in a solvent; the solvent is a polar solvent, at least one selected from water, methanol, ethanol, glycerin, propylene glycol, formamide, acetonitrile, n-butanol, dioxane, dichloromethane, acetone, dimethyl sulfoxide, dimethylformamide, ethyl acetate, and tetrahydrofuran;
  • a solvent is a polar solvent, at least one selected from water, methanol, ethanol, glycerin, propylene glycol, formamide, acetonitrile, n-butanol, dioxane, dichloromethane, acetone, dimethyl sulfoxide, dimethylformamide, ethyl acetate, and tetrahydrofuran
  • Step 2 Compound P2 is reacted with 4-aminotetrahydrofuran-3-ol to generate compound P3;
  • Reaction conditions carried out in a polar solvent containing a base; wherein the base is selected from at least one of pyridine, 2-picoline, 2,6-lutidine, 4-dimethylaminopyridine, triethylamine, diethylamine, N,N-diisopropylethylamine, dimethylisopropylamine, piperidine, 1-methylpiperidine, and 1-methylpyrrolidine; the polar solvent is according to step 1) as defined in
  • Step 3) compound P3 is oxidized to generate a compound of formula I;
  • Reaction conditions carry out under the condition of oxidizing agent;
  • Said oxidizing agent is inorganic oxidizing agent or organic oxidizing agent or mixed oxidizing agent;
  • the inorganic oxidant is selected from at least one of sodium dichromate, chromic acid, manganese dioxide, ammonium cerium nitrate, potassium permanganate, potassium ferrate, bromine element, iodine element, sodium hypochlorite, sodium chlorite, sodium bromate, sodium periodate, and iodine pentoxide;
  • the organic oxidant is selected from at least one of 2-iodylbenzoic acid, tetramethylpiperidine oxide, benzoyl peroxide, and cyclohexanone peroxide; At least one of pyridine and sulfur trioxide pyridine complex;
  • the oxidizing agent is preferably pyridinium chlorochromate, chromic anhydride pyridine complex, sulfur trioxide pyridine complex.
  • the present invention also provides a composition containing the cathepsin K inhibitor, which contains a therapeutically effective amount of one or more of the compounds or pharmaceutically acceptable salts thereof.
  • the present invention also provides the application of the cathepsin K inhibitor in the preparation of medicines for treating diseases targeted by cathepsin K.
  • the diseases targeted by cathepsin K include thyroid diseases, cardiovascular diseases, bone diseases, gum diseases and tumors.
  • the thyroid disease includes hyperthyroidism.
  • cardiovascular diseases include atherosclerosis, cardiac hypertrophy, and heart failure.
  • the bone diseases include osteoporosis, osteoarthritis, and rheumatoid arthritis.
  • the nail gingivitis includes gingivitis and periodontitis.
  • the tumor includes tumor invasion and tumor metastasis.
  • the disease targeting cathepsin K is osteoporosis.
  • the compound of the invention has high inhibitory rate to Cat K enzyme, low IC 50 value, and good inhibitory activity to Cat K enzyme.
  • the inhibitory rate of the compound to Cat K enzyme at 10 ⁇ M can reach more than 90%, and the IC 50 is less than 50nM.
  • the compound of the present invention has good selectivity: at the level of 1 ⁇ M and 10 ⁇ M, the inhibitory rates to Cat B enzyme and Cat S enzyme are both ⁇ 50%, and the IC50 values to Cat B enzyme and Cat S enzyme are both >10 ⁇ M, indicating that the compound of the present invention has good selectivity to Cat K enzyme.
  • the compound of the present invention has good druggability.
  • the cathepsin K inhibitor can be used to prepare and treat diseases characterized by abnormal expression or activation of cathepsin K, including thyroid diseases, cardiovascular diseases, bone diseases and oral diseases, specifically hyperthyroidism, atherosclerosis, cardiac hypertrophy, heart failure, osteoporosis, osteoarthritis, rheumatoid arthritis, gingivitis and periodontitis.
  • the compound of the invention can inhibit the formation of osteoclasts and can be used for the treatment of osteoporosis.
  • HATU 2-(7-Azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • DIPEA N,N-Diisopropylethylamine
  • C1-10 alkyl refers to a straight chain or branched chain hydrocarbon group containing 1-10 carbon atoms derived by removing a hydrogen atom on a single carbon atom of the parent alkane, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, n-hexyl, etc.
  • C1-6 alkyl refers to any straight or branched chain group containing 1-6 carbon atoms.
  • C1-10 alkoxy includes -O-C1-10 alkyl, which means that the C1-10 alkyl is bonded to an oxygen atom.
  • C1-6 alkoxy includes -O-C1-10 alkyl.
  • C3-10 cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon atoms and hydrogen atoms, which may include fused, bridged or spiro ring systems, having 3 to 10 carbon atoms, and which is saturated or unsaturated and which may be attached to the rest of the molecule by a single bond via any suitable carbon atom. Unless specifically stated otherwise in this specification, carbon atoms in a cycloalkyl group may be optionally oxidized.
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
  • C6-12 membered aromatic ring means a conjugated planar ring system.
  • the bonding between atoms is not a discontinuous alternation of single and double bonds, but is covered by a cloud of delocalized ⁇ electrons. It has 6-12 atoms, which can be carbon atoms, nitrogen atoms, sulfur atoms, and oxygen atoms.
  • the aromatic ring can be a single ring, Bicyclic, tricyclic or higher ring systems.
  • C1-10 and C1-C10 represent groups containing 1-10 carbon atoms
  • C6-12 heteroaromatic ring refers to a monocyclic or bicyclic aromatic ring containing 6-12 ring atoms, wherein 1, 2, 3 or 4 ring atoms are selected from nitrogen, sulfur or oxygen, wherein nitrogen or sulfur in the ring can be oxidized.
  • the heteroaromatic ring group is preferably a stable 5- to 10-membered aromatic group comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 5- to 8-membered aromatic group comprising 1 to 2 heteroatoms selected from nitrogen, oxygen and sulfur.
  • heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl.
  • C5-12 heterocycle is a saturated, unsaturated or partially saturated monocyclic or bicyclic ring containing 5-12 ring atoms, wherein 1, 2 or 3 ring atoms are selected from nitrogen, sulfur or oxygen, and the ring may be connected by carbon or nitrogen, wherein the -CH2- group in the ring is optionally replaced by a -C(O) group; wherein the nitrogen or sulfur atom in the ring can be optionally oxidized to form N-oxide or S-oxide; wherein -NH- in the ring is optionally replaced by acetyl, formyl, Methyl or methylsulfonyl substitution.
  • the pharmaceutical composition of the present invention includes: the compound of formula I or formula II described in the first aspect of the present invention, or its optical isomers, pharmaceutically acceptable salts, and prodrugs.
  • the term “pharmaceutically acceptable salt” refers to a salt that is suitable for tissue contact of the subject without causing undue side effects, and the salts in the present application are mainly pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to a salt formed with an inorganic or organic acid that retains the biological effectiveness of the free base without other side effects.
  • Inorganic acid salts include hydrochloride, hydrobromide, sulfate, nitrate, phosphate, etc.; organic acid salts include formate, acetate, 2,2-dichloroacetate, trifluoroacetate Acetate, propionate, caproate, caprylate, caprate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, laurate, malate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesul
  • “Pharmaceutically acceptable base addition salt” refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects.
  • Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
  • Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, those of primary, secondary, and tertiary amines, substituted amines, including natural substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, Lucaine, choline, betaine, ethylenediamine, glucosamine methyl glucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resin, etc.
  • Preferred organic bases include the isomaxamines diethylamine, ethanolamine, trimethylamine, dicyclohexylamine,
  • the present invention also includes prodrugs of the above-mentioned compounds.
  • prodrug means a compound which can be converted into the biologically active compound of the present invention under physiological conditions or by solvolysis. Accordingly, the term “prodrug” refers to a pharmaceutically acceptable metabolic precursor of a compound of the present invention.
  • Prodrugs may be inactive when administered to an individual in need thereof, but are converted in vivo to the active compound of the invention.
  • Prodrugs are generally transformed rapidly in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood.
  • Prodrug compounds typically provide solubility, tissue compatibility or sustained release advantages in mammalian organisms.
  • the specific prodrug preparation method can refer to Saulnier, M.G., et al., Bioorg.Med.Chem.Lett.1994, 4, 1985-1990; Greenwald, R.B., et al., J.Med.Chem.2000, 43, 475.
  • pharmaceutically acceptable refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention, and is relatively nontoxic, that is, the substance can be administered to an individual without causing an adverse biological response or interacting in an adverse manner with any component contained in the composition.
  • treatment and other similar synonyms include the following meanings:
  • Fig. 1 is the effect of compound K18 on body weight of ICR mice; (A) single administration experiment; (B) multiple administration experiment.
  • Fig. 2 is the histopathological changes of the liver, kidney and heart of the mice in the vehicle group and after multiple administrations (50 mg/kg) and single administration (500 mg/kg) of compound K18. Scale bar: 100 ⁇ M.
  • intermediate M4 was prepared.
  • the preparation method of this example refers to the preparation steps of Example 19 to obtain a white solid, compound K28, with a yield of 51%. Its 1 HNMR (400MHz, DMSO) ⁇ 11.37(s,1H),8.34–8.04(m,1H),7.38–7.20(m,1H),6.96–6.88(m,2H),4.78–4.52(m,2H),4.51–3.44(m,7H),3.08–2.90(m,2H ), 2.81–2.57(m,2H), 1.73(m,4H), 1.25(m,4H).
  • the preparation method of this example refers to the preparation steps of Example 19 to obtain a white solid, compound K32, with a yield of 58%. Its 1 H NMR (400MHz, DMSO) ⁇ 11.07(s,1H),8.30–8.03(m,1H),6.91–6.75(m,1H),6.60–6.52(m,1H),4.71–4.45(m,2H),4.45–3.88(m,7H),3.87–3.44(s,3H ), 3.04–2.75(m,2H), 2.70–2.54(m,2H), 1.82–1.26(m,8H).
  • the preparation method of this example refers to the preparation steps of Example 1, using 4-chlorobenzyl bromide as a raw material to obtain a white solid product with a yield of 55%.
  • 1 H NMR(400MHz,DMSO-d 6 ) ⁇ 8.62(s,1H),7.36(d,J 8.4Hz,2H),7.21–7.15(m,3H),4.88(s,2H),3.56(s,2H),0.95(s,9H).13C NMR(101MHz,CDCl3) ⁇ 162.69,159.34,141.29,136.28,132.79,128.68,128.36,116.23,112.24,57.96,51.89,34.75,28.64.HRMS(ESI)for C 17 H 19 ClN 4 [M+H] + :calcd,315.1371;found,315.1370.
  • the preparation method of this example refers to the preparation steps of Example 1, using 4-bromobenzyl bromide as a raw material to obtain a white solid product with a yield of 55%.
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 50%.
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 27%.
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 53%.
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 46%.
  • 1 HNMR(300MHz,DMSO-d6) ⁇ 8.63(s,1H),7.56–7.43(m,4H),7.23–7.13(m,3H),7.03–6.93(m,2H),4.93(s,2H),4.71(d,J 4.2Hz,1H),3.69–3.50(m,5H),2.95–2.81(m,2H),1.87–1.74(m,2H),1.54–1.39(m,2H),0.97(s,9H).13C NMR(101MHz,CDCl 3 ) ⁇ 162.88,159.33,150.43,141.28,139.75,135.74,131.56,127.62,127.29,126.59,116.51,116.34,112.02,67.88,57.70,52.03,47.07,34.77,34.09,28.69.HR
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 54%.
  • the preparation method of this example refers to the preparation steps of Example 1 to obtain a white solid product with a yield of 51%.
  • HRMS(ESI)for C 28 H 33 ClN 6 [M+H] + :calcd,489.2528;found,489.2519.
  • K41-1 was obtained as a white solid product with a yield of 64%.
  • the intermediate K41-1 (330 mg, 1.41 mg) was added to 10 mL of cold 4N hydrochloric acid/dioxane solution, and placed in an ice bath to react for 30 minutes. After the reaction was detected by TLC, the reaction solution was evaporated under reduced pressure, and a small amount of toluene was added until the reaction solution was completely removed. Then the residue was dissolved in 10 mL of DMF, potassium carbonate (487 mg, 3.53 mmol) and chloroacetone (195 mg, 2.11 mmol) were added in sequence, and the temperature of the reaction solution was raised to 80° C. for 2 hours. After the reaction was detected by TLC, it was cooled to room temperature.
  • the obtained carboxylic acid was added to 10 mL of anhydrous tetrahydrofuran, HATU (787 mg, 2.07 mmol), triethylamine (524 mg, 5.18 mmol) and N-methylpiperazine (249 mg, 2.48 mmol) were sequentially added, and the reaction was carried out at room temperature for 2 hours. TLC detection After the reaction was completed, the reaction solution was diluted with 40 mL of ethyl acetate, washed successively with saturated sodium carbonate solution (15 mL ⁇ 2), dilute hydrochloric acid solution (15 mL ⁇ 2) and saturated sodium chloride solution (15 mL ⁇ 2), and then dried with anhydrous sodium sulfate for 4 hours.
  • Embodiment 46 compound is to the inhibitory effect of Cat K enzyme
  • Reagent Information Cat K Inhibitor Screening Kit: Lot#, 6L23K01500; Supplier, BiVision.
  • Drug preparation the compound was dissolved in DMSO and prepared as a 10 mM stock solution. Use Buffer to prepare the desired concentration.
  • Cathepsin K (CTSK, EC 3.4.22.38) is a lysosomal cysteine protease involved in osteoclastic bone remodeling and resorption and also degrades collagen, gelatin, and elastin.
  • Biovision's Cathepsin K Inhibitor Screening Kit exploits the ability of active cathepsin K to cleave synthetic AFC-based peptide substrates to release AFC, which can be easily quantified using a fluorometer or fluorescent microplate reader. In the presence of cathepsin K-specific inhibitors, cleavage of this substrate is reduced/eliminated, resulting in reduced or complete loss of AFC fluorescence.
  • This simple and high-throughput adaptable assay kit can be used to screen/research/characterize potential inhibitors of cathepsin K.
  • Inhibition rate (%) (EC slope - S slope) / EC slope ⁇ 100
  • the screening method is the same as 1.1, the concentration of the compound to be tested is set between 0.1nM-10 ⁇ M, 4-5 concentrations are selected for detection, the IC 50 curve is drawn, and the IC 50 value is calculated.
  • A, B and C represent the activity range of IC50 values, where A: ⁇ 10nM, B: 10-100nM, C: 100-500nM.
  • the compound of the invention has high inhibitory rate to Cat K enzyme, low IC 50 value, and good inhibitory activity to Cat K enzyme.
  • the IC 50 values of some compounds such as K13 and K15 are less than 10nM, and the IC 50 values of some compounds such as K1 and K18-K22 are all less than 100nM, so the compounds of the present invention have better inhibitory effect on Cat K enzyme.
  • Inhibition rate (%) (EC slope - S slope) / EC slope ⁇ 100
  • the screening method is the same as above, the concentration of the compound to be tested is set between 0.1nM-10 ⁇ M, 4-5 concentrations are selected for detection, the IC 50 curve is drawn, and the IC 50 value is calculated.
  • Inhibition rate (%) (EC slope - S slope) / EC slope ⁇ 100
  • the screening method is the same as above, the concentration of the compound to be tested is set between 0.1nM-10 ⁇ M, 4-5 concentrations are selected for detection, the IC 50 curve is drawn, and the IC 50 value is calculated.
  • >> indicates that the inhibition rate does not exceed 20% at the test concentration; “>” indicates that the inhibition rate is greater than 35% at the test concentration; “ ⁇ ” indicates that the inhibition rate is about 50% at the test concentration; “ ⁇ ” indicates that the inhibition rate is less than 50% at the test concentration.
  • K2 molecular formula C23H27N3O4, 4.6mg
  • K3 molecular formula C23H26FN3O4, 5.0mg
  • K4 molecular formula C23H25F2N3O4, 5.6mg
  • Electrospray ion source ESI
  • ion spray voltage 4500V
  • ion source temperature 450°C
  • air curtain gas pressure 35psi
  • declustering voltage 80V.
  • the sample solution was injected and analyzed under the above chromatographic and mass spectrometric conditions, and the peak area was recorded.
  • the weighted method (the weighting coefficient is 1/x2) is used for linear regression.
  • the above-mentioned compounds Compared with Ref-03, the above-mentioned compounds have lower internal clearance rates of liver microparticles in rats, among which the clearance rate of compound K4 is reduced by 2 times, and the clearance rate of other compounds is less than 250 of Ref-03.
  • the half-life of Ref-03 is 0.6 hours, and the half-life of the compounds of the present invention is greater than 0.6 hours. Therefore the metabolic stability of the compound of the present invention is better.
  • RAW 264.7 cells were seeded in 96-well plates at a density of 1 ⁇ 105/well and cultured in DMEM medium containing 10% FBS and 1% penicillin/streptomycin. The cells were cultured at a constant temperature of 37°C and 5% CO2 Cultivated in a box. After culturing for 24 hours, different concentrations of inhibitor working solution were added to the administration group, and an equal volume of PBS working solution was added to the control group. After continuing to culture for 2 days, the culture supernatant was removed, washed with PBS three times, and the survival rate of the cells was detected with a CCK8 cell proliferation detection kit.
  • the survival rate was calculated by the following formula:
  • Cell survival rate (%) [(Average absorbance value of administration group-Average absorbance value of blank wells)/(Average absorbance value of control group-Average absorbance value of blank group)] ⁇ 100.
  • RAW 264.7 cells were seeded in 96-well plates at a density of 1 ⁇ 10 5 /well, and cultured in DMEM medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were cultured in a constant temperature incubator at 37°C and 5% CO2. Add 100 ng/mL RANKL induction solution to each well of the treatment group and model group to culture osteoclasts, and change the medium (including RANKL) every 2-3 days.
  • the treatment group was added different concentrations of inhibitor working solution, and the model group was added with an equal volume of PBS working solution, and continued to culture for 24 hours; the control group did not add RANKL induction solution and inhibitor working solution, and added the same total volume of PBS working solution.
  • the culture supernatant was removed, washed with PBS three times, the cells were stained with the TRAP staining kit, and the multinucleated osteoclasts were observed and counted under an optical microscope.
  • the experimental subjects were male ICR mice of 6-8 weeks. After one week of adaptive feeding, they were randomly divided into groups according to body weight, and then compounds of different concentrations were prepared for single administration and multiple administration experiments by intraperitoneal injection (i.p), and the vehicle with the same composition was used as a reference.
  • i.p intraperitoneal injection
  • a mouse model of osteoporosis was established by subcutaneously injecting dexamethasone into male C57BL/6 mice, the model Eight days after establishment, the model mice were administered intraperitoneally at dosages of 12 mg/kg, 24 mg/kg and 36 mg/kg, and the Cat K inhibitor Bascatib was used as a positive control.
  • the patients were anesthetized and dissected, the serum was preserved, and the content of the bone resorption biomarker CTX in the blood was detected by ELISA method, and one side of the femur was taken to test the bone density.
  • the therapeutic effect of Cat K inhibitor on osteoporosis was evaluated. The pre-experimental effect is obvious. Currently in formal experimentation.
  • the bone metastasis model of prostate cancer is established by puncture injecting C4-2B cells into the tibia of NOD-SCID mice, and the therapeutic effect of the compound of the present invention on bone metastasis is further studied. After 4 weeks of modeling, the model mice were given intraperitoneal injection at dosages of 25 mg/kg and 50 mg/kg, and the commonly used anti-bone metastasis drug zoledronic acid was used as a positive control. The drug was administered once a day continuously for 4 weeks, during which the body weight changes and tumor volume changes of the mice were observed and recorded.
  • mice After the administration, the mice were sacrificed, and the content of prostate specific antigen (PSA) in the plasma was tested by ELISA, and then the tibia bone density of the mice was tested, and pathological sections were made to test the pathological changes of the bone tissue.
  • PSA prostate specific antigen
  • test results preliminarily show that compound K18 can inhibit the migration, invasion and adhesion process of C4-2B cells in a concentration-dependent manner, indicating that Cat K inhibitors can effectively exert anti-tumor activity by affecting the metastasis process of tumors.
  • Test substances K29 (molecular weight 439.21, mass 27 mg), K31 (molecular weight 457.20, mass 14 mg+20 mg).
  • HS-15 is of analytical grade
  • carboxymethylcellulose sodium (CMC-Na) is of pharmaceutical grade
  • formic acid, methanol, and acetonitrile are of chromatography grade
  • water is of purified water.
  • Electrospray ion source ESI
  • ion spray voltage 3500V
  • ion source temperature 300°C
  • auxiliary gas 45Arb
  • sheath gas 10Arb.
  • Intravenous and intraperitoneal administration solution prepared with 0.5% HS-15 normal saline solution, the concentration is 0.2mg/mL;
  • Suspension for intragastric administration grind and suspend with 0.5% CMC-Na aqueous solution, the concentration is 0.5 mg/mL.
  • the two compounds K29 and K31 are administered through intravenous injection and intragastric administration.
  • the volume of intravenous administration was 5mL/kg, and 0.2mL blood was collected from the jugular vein at 2min, 10min, 30min, 1h, 2h, 4h, 7.5h, and 24h after administration, respectively.
  • 10mL/kg, 0.2mL blood was collected from the jugular vein at 5min, 15min, 30min, 1h, 2h, 4h, 8h, and 24h after administration. All blood samples were anticoagulated with heparin, centrifuged at 4000g for 10min, and the supernatant was taken Plasma was frozen for testing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

涉及一种组织蛋白酶K抑制剂，结构如式(0)和/或式(II)所示，作为亲电子基团的嘧啶氰基或酮基为关键基团，对组织蛋白酶K发挥良好的抑制作用。还提供了其制备方法和应用。所提供的组织蛋白酶K抑制剂具有较高的抑制作用和选择性，有望用于包括甲状腺疾病、心血管疾病、骨疾病和牙龈病在内的疾病治疗。

Description

一种组织蛋白酶K抑制剂与其制备方法及其应用 技术领域
本发明涉及医药化学领域，具体涉及抑制组织蛋白酶K激酶活性的化合物、它们的制备方法及制备用于与组织蛋白酶K活性相关或以组织蛋白酶K活性为特征的疾病中的用途，如骨质疏松。
技术背景
骨质疏松症简称骨质疏松，是一种全身骨量减少、骨密度降低，进而导致患者骨折风险增加的代谢障碍性疾病。随着人口老龄化的加剧，该疾病涉及的健康问题日益严重，骨质疏松患者的骨折几率大大增加，为社会和家庭带来了沉重的负担，严重影响了人们的生活。骨质疏松的发病机制是破骨细胞介导的骨吸收和成骨细胞介导的骨形成失衡所导致，目前市场上常用的骨质疏松治疗药物有骨吸收抑制剂如双磷酸盐，和骨形成促进剂，但这两种药都存在一定的缺陷。长期使用骨吸收抑制剂会使骨细胞的分化增殖受到影响，进一步导致“低骨转换状态”的发生；骨形成促进剂则会增加患者患骨肉瘤的概率。
由于目前市场上存在的药物均存在一定缺陷，因此研究能够在发挥骨质疏松治疗作用的同时，不会影响成骨细胞和破骨细胞的增殖、分化，避免低骨转换状态的发生的新型骨质疏松治疗药物，是目前的研究方向。
组织蛋白酶K(Cathepsin K，Cat K)属于木瓜蛋白酶家族的半胱氨酸蛋白酶，在破骨细胞中大量存在，目前成为骨质疏松治疗的新靶点。人体的骨基质由25％的水、25％的有机基质和50％的矿物基质组成，其中有机质的90％组成成分是Ⅰ型胶原蛋白，Ⅰ型胶原蛋白的降解是破骨细胞介导的骨吸收的关键过程，而Cat K对Ⅰ型胶原蛋白的降解起主导作用，Cat K抑制剂通过阻断基质胶原蛋白的降解来抑制成熟破骨细胞的再吸收，与此同时，Cat K抑制剂可维持破骨细胞的存活数量，这使得破骨细胞和成骨细胞的耦合信号保持完整，从而避免了“低骨转换状态”的发生。另外Cat K在甲状腺疾病、心血管疾病和牙龈病的致病过程中起重要作用。Cat K异常表达或活化为特征的疾病，包括甲状腺疾病、心血管疾病、骨疾病和牙龈病，具体为甲状腺功能亢进、动脉粥样硬化、心肌肥厚、心力衰竭、骨质疏松症、骨关节炎、类风湿性关节炎、牙龈炎和牙周炎。近年关于Cat K的 研究越来越多，冠状动脉粥样硬化等病理状态下可引起内皮细胞分泌Cat K增加。Cat K与心肌肥厚、心力衰竭的发生发展有着非常紧密的联系。Garg等(Garg G，Pradeep AR，Thorat MK，et al.Effect of nonsurgical periodontal therapy on crevicular fluid levels of Cathepsin K in periodontitis.Arch Oral Biol，54:1046-1051)通过牙周炎患者基础治疗前后龈沟液中Cat K的变化，证明基础治疗后，随着牙周炎患者临床牙龈指数，牙周探诊深度及附着丧失减少，Cat K的水平也随之降低，Cat K作为牙周炎骨吸收的标记物，在牙周炎治疗中应得到进一步的关注和研究。
目前Cat K抑制剂以及临床研究阶段报道的各类抑制剂的活性均已经得到了很大的提高。但是，仍旧没有针对于该靶点的上市药物，其主要原因是化合物的选择性较差，对其他亚型如B型和S型具有较高的抑制活性，导致药物副作用的产生。因此以减少副作用为目标，开发研究高效、选择性新型Cat K抑制剂，是目前的主要研究方向。
鉴于Cat B与Cat K同属于半胱氨酸蛋白酶，而Cat L为嗜酸性蛋白水解酶，且Cat L来源困难，故本发明设计并合成的一种氰基取代嘧啶类化合物针对K、B和S测定了活性，发现具有良好的选择性，以期用于治疗与Cat K活性相关或以Cat K活性为特征的疾病。
发明内容
本发明提供了一种作用于Cat K的新型酮类化合物和/或腈类化合物及其药学上可接受的盐，与其制备方法及其应用。
本发明提供一种腈类化合物，其结构通式如下所示：
其中：式0中，X为C或N；
R1选自H、取代或未取代的C1-10烷基、取代或未取代的C3-C10环烷基；其中，所述的取代基选自卤素、氨基、氰基、羟基、醛基、羧基、砜基；
R*选自卤素或C1-6烷基；
Y为环基，位于所连接芳香环的任意位置，通过1或2个碳原子与芳香环相连，任选为C3-10环烷基、C6-12芳香环、C5-12杂环；
其中，所述的C6-12芳香环包含C6-12芳环和C6-12杂芳环；其中所述C6-12杂芳环含有至少一个杂原子；其中所述C5-12杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
e为0或1；当e为0时，R5直接连接芳香环任意位置；
R5选自H、卤素、氨基、氰基、C1-10烷基、C1-10烷氧基、C3-10环烷基、取代或未取代的C3-10杂环烷基、-S(O)2R2、-C(O)R2、-NR3R4、-C(O)NHR7、-SR6、-OR6；
其中，所述C3-10杂环烷基的取代基选自羟基、C1-10烷基；
其中，所述C1-10烷基可进一步被羟基、-C(O)R2取代；
其中，所述R2选自H、氨基、卤素、取代或未取代的C1-6烷基、C1-6烷氧基、C3-8环烷基或C3-8杂环烷基；其中，所述C1-6烷基、C1-6烷氧基、C3-8环烷基或C3-8杂环烷基的取代基为C1-6烷基。
其中，所述R3、R4分别独立选自H、-C(O)R8；或者R3、R4与它们相连的N共同形成至少含有一个N的4-8元环；其中，所述R8选自被哌嗪基或甲基哌嗪取代的C1-6烷基
其中，所述R6选自C1-6烷基；
其中，所述R7选自C1-6烷基，其中C1-6烷基可进一步被-C(O)R9取代；其中R9选自哌嗪基或甲基哌嗪基；
其中，所述C3-10杂环烷基或C3-8杂环烷基含有1-3个杂原子，所述杂原子任选O、N或S；
其中，所述卤素为单取代或者多取代，选自F、Cl、Br、I。
当t为0，R*为H时，式0化合物如为式I所示：
其中：式I中，X为C或N；
R1选自H、取代或未取代的C1-10烷基、取代或未取代的C3-C10环烷基；其中，所述的取代基选自卤素、氨基、氰基、羟基、醛基、羧基、砜基；
Y为环基，位于所连接芳香环的任意位置，任选为C3-10环烷基、C6-12芳香环、C5-12杂环；
其中，所述的C6-12芳香环包含C6-12芳环和C6-12杂芳环；其中所述C6-12杂芳环含有至少一个杂原子；其中所述C5-12杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
R5选自H、卤素、氨基、氰基、C1-10烷基、C1-10烷氧基、C3-10环烷基、-S(O)2R2、-C(O)R2、-NR3R4、-SR6、-OR6；其中，所述R2选自H、氨基、卤素、C1-6烷基、C1-6烷氧基、C3-8环烷基；其中，所述R3、R4与它们相连的N共同形成至少含有一个N的4-8元环；其中所述R6选自C1-6烷基；
其中，所述卤素为单取代或者多取代，选自F、Cl、Br、I。
进一步的，X为C；
R1选自C1-6烷基、C4-C8环烷基；
Y为环基，位于芳香环的对位，任选为C4-8环烷基、C6-10芳香环、C5-10杂环；
其中，所述的C6-10芳香环包含C6-10芳环和C6-10杂芳环；其中所述C6-10杂芳环含有至少一个杂原子；其中所述C5-10杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
R5选自H、卤素、氨基、氰基、C1-6烷基、C1-6烷氧基、C3-8环烷基、-S(O)2R2、-C(O)R2、-NR3R4、-SR6、-OR6；其中，所述R2选自H、氨基、卤素、C1-6烷基、C1-6烷氧基、C3-8环烷基；其中，所述R3、R4与它们相连的N共同形成至少含有一个N的5-8元环；其中所述R6选自C1-6烷基。
其中，所述卤素为单取代或者多取代，选自F、Cl、Br。
进一步的，X为C；
R1选自C1-6烷基、C5-8环烷基；
Y为环基，位于芳香环的对位，任选为C5-8环烷基、C6-8芳香环、C5-8杂环；
其中，所述C6-8芳香环包含C6-8芳环和C6-8杂芳环；其中所述C6-8杂芳 环含有至少一个杂原子；其中所述C5-8杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
R5选自H、卤素、氨基、氰基、C1-3烷基、C1-3烷氧基、-S(O)2R2、-C(O)R2、-NR3R4、-SR6、-OR6；其中，所述R2选自氨基、卤素、C1-3烷基；其中，所述R3、R4与它们相连的N共同形成至少含有一个N的5-8元环；其中所述R6选自C1-3烷基。
其中，所述卤素为单取代或者多取代，选自F、Cl、Br。
在一些实施例中，R1选自新戊基、环己基。
在一些实施例中，Y选自以下基团：苯基、吡啶基、噻吩基、噻唑基。
在一些优选实施例中，Y选自苯基、噻唑基。
在一些实施例中，R5选自H、F、Cl、氰基、甲基、甲硫基、甲氧基、甲砜基、甲羰基、甲基哌嗪基。
在一些优选实施例中，R5选自甲基、甲基哌嗪基。
本发明提供一种酮类组织蛋白酶K抑制剂，其结构通式如下所示：
其中，R1、R2各自独立选自H、卤素、氰基、氨基、取代或非取代的C1-6烷基、取代或非取代的C1-6烷氧基，所述取代的C1-6烷基或取代的C1-6烷氧基进一步的被至少一个卤素或羟基取代；
t为化学键，任选中至少一种。
进一步的，其中R1、R2各自独立选自H、卤素、C1-3烷基、C1-3烷氧基，所述C1-3烷基或C1-3烷氧基进一步的被至少一个卤素取代。
进一步的，其中R1、R2各自独立选自H、卤素、C1-3烷基、C1-3烷氧基，所述C1-3烷基或C1-3烷氧基进一步的被至少一个F取代。
所述C1-3烷基为甲基、乙基、丙基或异丙基。
所述C1-3烷氧基为甲氧基、乙氧基、丙氧基、异丙氧基、一氟甲氧基、二氟甲氧基或三氟甲氧基。
所述C1-3烷氧基为甲氧基或三氟甲基。
所述C1-3烷氧基为三氟甲基
在一些实施例中，R1、R2各自独立选自H、F、Cl、Br、甲氧基、三氟甲氧基。
在一些优选实施例中，R1、R2各自独立选自H和F。
所述卤素选自F、Cl、Br、I。
本发明所提供的化合物，包括以下具体结构：
1)2-[(2,2-二甲基丙基){[4-(4-甲基哌嗪-1-基)苯基]甲基}氨基]嘧啶-4-甲腈；
2)2-[(2,2-二甲基丙基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈；
3)2-[(2,2-二甲基丙基)({4-[4-(甲基硫基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈；
4)2-[(2,2-二甲基丙基){[4-(4-氟苯基)苯基]甲基}氨基]嘧啶-4-甲腈；
5)2-[(2,2-二甲基丙基){[4-(4-甲氧基苯基)苯基]甲基}氨基]嘧啶-4-甲腈；
6)2-[(2,2-二甲基丙基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈；
7)2-({[4-(5-氰基噻吩-2-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈；
8)2-({[4-(6-氯吡啶-3-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈；
9)2-({[4-(3,4-二氯苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈；
10)2-[(2,2-二甲基丙基){[4-(5-甲基噻吩-2-基)苯基]甲基}氨基]嘧啶-4-甲腈；
11)4-(4-{[(4-氰基嘧啶-2-基)(2,2-二甲基丙基)氨基]甲基}苯基)苯甲酸甲酯；
12)2-({[4-(4-氯-3-氟苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈；
13)2-[(2,2-二甲基丙基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈；
14)2-[(环己基甲基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈；
15)2-[(环己基甲基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈；
16)2-[(环己基甲基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈；
17)2-(新戊基(4-(噻唑-4-基)苄基)氨基)嘧啶-4-甲腈；
18)2-((4-(2-(4-甲基哌嗪-1-基)噻唑-4-基)苄基)(新戊基)氨基)嘧啶-4-甲腈；
19)(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
20)(1R，2R)-2-(2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
21)(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
22)(1R，2R)-2-(6，8-二氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
23)(1R,2R)-2-(8-氯-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
24)(1R,2R)-2-(8-溴-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
25)(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
26)(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
27)(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
28)(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
29)(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
30)(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
31)(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
32)(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺。
33)2-((4-氯苄基)(新戊基)氨基)嘧啶-4-甲腈；
34)2-((4-溴苄基)(新戊基)氨基)嘧啶-4-甲腈；
35)2-((萘-2-基甲基)(新戊基)氨基)嘧啶-4-甲腈；
36)2-(新戊基(喹啉-2-基甲基)氨基)嘧啶-4-甲腈；
37)2-(((4’-(4-(2-羟乙基)哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
38)2-(((4’-(4-羟基哌啶-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
39)2-(((2-甲基-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
40)2-(((2-氯-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
41)2-(新戊基(4-(4-(2-氧丙基)哌嗪-1-基)苄基)氨基)嘧啶-4-甲腈；
42)2-(异丁基((4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)甲基)氨基)嘧啶-4-甲腈；
43)N-(4-((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)苯基)-2-(4-甲基哌嗪-1-基)乙酰胺；
44)2-((4-(4-甲基哌嗪-1-羰基)苄基)(新戊基)氨基)嘧啶-4-甲腈；
45)4-(((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)-N-(2-(4-甲基哌嗪-1-基)-2-氧乙基)苯甲酰胺。
本发明的另一目的是提供上述化合物及其药用盐的制备方法，式I的制备方法包括以下步骤：
其中R1、R5、X、Y如上述所定义；
其中L为卤素，卤素选自F、Cl、Br；
步骤1)：中间体T3与化合物T4生成化合物T5；
反应条件：在碱性溶剂中进行；
其中所述碱为无机碱，选自碳酸铯、碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、氨水、氢化钠、氢氧化钠、氢氧化钾、氢氧化钙中至少一种；
所述溶剂选自水、甲醇、乙醇、甘油、丙二醇、甲酰胺、乙腈、正丁醇、二氧六环、二氯甲烷、氯仿、丙酮、二甲基亚砜、二甲基甲酰胺、醋酸乙酯或四氢呋喃中至少一种；
步骤2)：化合物T5与化合物T6反应生成式Ⅰ化合物；
反应条件：在碱性溶剂中加热反应；
其中所述碱和溶剂如步骤1)中所定义；
其中所述加热温度为40-100℃。
式II的制备方法包括以下步骤：
步骤1)化合物P1与(3aR,7aS)-六氢异苯并呋喃-1,3-二酮反应生成化合物P2；反应条件：在溶剂中进行；所述溶剂为极性溶剂，选自水、甲醇、乙醇、甘油、丙二醇、甲酰胺、乙腈、正丁醇、二氧六环、二氯甲烷、丙酮、二甲基亚砜、二甲基甲酰胺、醋酸乙酯、四氢呋喃中至少一种；
步骤2)化合物P2与4-氨基四氢呋喃-3-醇反应生成化合物P3；
反应条件：在含碱的极性溶剂中进行；其中所述碱选自吡啶、2-甲基吡啶、2,6-二甲基吡啶、4-二甲氨基吡啶、三乙胺、二乙胺、N,N-二异丙基乙胺、二甲基异丙胺、哌啶、1-甲基哌啶、1-甲基吡咯烷中至少一种；所述极性溶剂根据步骤1) 中所定义；
步骤3)化合物P3经氧化反应生成式Ⅰ化合物；
反应条件：在氧化剂的条件下进行；所述氧化剂为无机氧化剂或有机氧化剂或混合氧化剂；
其中所述无机氧化剂选自重铬酸钠、铬酸、二氧化锰、硝酸铈铵、高锰酸钾、高铁酸钾、溴单质、碘单质、次氯酸钠、亚氯酸钠、溴酸钠、高碘酸钠、五氧化二碘中至少一种；所述有机氧化剂选自2-碘酰基苯甲酸、四甲基哌啶氧化物、过氧化苯甲酰、过氧化环己酮中至少一种；所述混合氧化剂选自氯铬酸吡啶盐、铬酐吡啶复合物、重铬酸吡啶、三氧化硫吡啶复合物中至少一种；
进一步地，氧化剂优选为氯铬酸吡啶盐、铬酐吡啶复合物、三氧化硫吡啶复合物。
本发明还提供了含有所述的组织蛋白酶K抑制剂的组合物，其中含有治疗有效量的一种或多种所述的化合物或其药学上可接受的盐。
本发明还提供了所述组织蛋白酶K抑制剂在制备用于治疗以组织蛋白酶K为靶向的疾病的药物中的应用。
进一步的，所述以组织蛋白酶K为靶向的疾病包括甲状腺疾病、心血管疾病、骨疾病和牙龈病和肿瘤。
进一步的，所述甲状腺疾病包括甲状腺功能亢进。
进一步的，所述心血管疾病包括动脉粥样硬化、心肌肥厚、心力衰竭。
进一步的，所述骨疾病包括骨质疏松症、骨关节炎、类风湿性关节炎。
进一步的，所述甲牙龈病包括牙龈炎和牙周炎。
进一步的，所述肿瘤包括肿瘤侵袭和肿瘤转移。
进一步的，所述以组织蛋白酶K为靶向的疾病为骨质疏松症。
与现有技术相比，本发明的优点和技术效果在于：
本发明化合物对Cat K酶的抑制率高，IC50数值低，对Cat K酶有很好的抑制活性。化合物在10μM对Cat K酶的抑制率能达到90％以上，IC50小于50nM。
本发明化合物选择性好：在1μM和10μM水平，对Cat B酶、Cat S酶的抑制率均<50％，对Cat B酶和Cat S酶的IC50值均>10μM，表明本发明化合物对Cat K酶具有很好的选择性。
本发明化合物具有良好的成药性。
该组织蛋白酶K抑制剂可用于制备治疗以组织蛋白酶K异常表达或活化为特征的疾病，包括甲状腺疾病、心血管疾病、骨疾病和口腔疾病，具体为甲状腺功能亢进、动脉粥样硬化、心肌肥厚、心力衰竭、骨质疏松症、骨关节炎、类风湿性关节炎、牙龈炎和牙周炎。本发明化合物能够抑制破骨细胞的生成，可用于制备骨质疏松症的治疗。
本发明的中术语：
1.缩写和定义
DMF：N,N-二甲基甲酰胺
DMSO：二甲基亚砜
DMAP：4-二甲氨基吡啶
DCM：二氯甲烷
HATU：2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
DIPEA：N,N-二异丙基乙胺
2.其他术语
术语“C1-10烷基”是指含1-10个碳原子的通过除去母体烷的单个碳原子上的一个氢原子衍生的直链或支链烃基，例如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、新戊基、正己基等。术语“C1-6烷基”指的是任意的含有1-6个碳原子的直连或支链基团。
术语“C1-10烷氧基”包括-O-C1-10烷基，指C1-10烷基与氧原子相连。
术语“C1-6烷氧基”包括-O-C1-10烷基。
术语“C3-10环烷基”指仅由碳原子和氢原子组成的稳定的非芳香族单环或多环烃基,其可包括稠合环体系、桥环体系或螺环体系，具有3至10个碳原子，且其为饱和或不饱和并可经由任何适宜的碳原子通过单键与分子的其余部分连接。除非本说明书中另外特别指明，环烷基中的碳原子可以任选地被氧化。环烷基的实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基等。
术语“C6-12元芳香环”表示具有共轭的平面环体系，原子间成键并不是不连续的单双键交替，而是被离域π电子云覆盖，具有6-12个原子，可以为碳原子、氮原子、硫原子、氧原子。除非本说明书中另外特别指明，否则芳香环可为单环、 双环、三环或更多环的环体系。
术语“C1-10”、“C1-C10”的表述形式表示含有1-10个碳原子的基团
术语“C6-12杂芳环”为含有6-12环原子的单环或双环芳环，其中1、2、3或4个环原子选自氮、硫或氧，其中环中的氮或硫可以被氧化。就本发明的目的而言，杂芳环基优选为包含1至3个选自氮、氧和硫的杂原子的稳定的5元至10元芳香性基团,更优选为包含1至2个选自氮、氧和硫的杂原子的稳定的5元至8元芳香性基团。杂芳基的实例包括但不限于噻吩基、咪唑基、吡唑基、噻唑基、噁唑基、噁二唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基。
术语“C5-12杂环”是含有5-12个环原子的饱和的、不饱和的或部分饱和的单环或双环，其中1、2或3个环原子选自氮、硫或氧，所述环可以由碳或氮连接，其中环中的-CH2-基团任选被-C(O)基团取代；其中环中的氮或硫原子可以任选被氧化形成N-氧化物或S-氧化物；其中环中的-NH-任选被乙酰基、甲酰基、甲基或甲磺酰基取代。
除非另有定义，否则本文所有科技术语具有的涵义与权利要求主题所属领域技术人员通常理解的涵义相同。
应理解，上述简述和下文的详述为示例性且仅用于理解，而不对本发明主题作任何限制。此外，所用术语“包括”以及其他形式，例如“包含”、“含”和“含有”并非限制性。
本文所用的章节标题仅用于组织文章的目的，而不应被理解为对所述主题的限制。本申请中引用的所有文献或文献部分包括但不限于专利、专利申请、文章、书籍、操作手册和论文，均通过引用方式整体并入本文。
本发明所述的药物组合物包括:本发明第一方面所述的式I或式II化合物，或其光学异构体，药学上可接受的盐，前药。
在本申请中，除非特别说明，术语“药学上可接受的盐”指适合于对象的组织接触，而不会产生不适度的副作用的盐，本申请中的盐主要为药学上可接受的酸加成盐和药学上可接受的碱加成盐。
“药学上可接受的酸加成盐”是指能够保留游离碱的生物有效性而无其它副作用的，与无机酸或有机酸所形成的盐。无机酸盐包括盐酸盐、氢溴酸盐、硫酸盐、硝酸盐、磷酸盐等；有机酸盐包括甲酸盐、乙酸盐、2,2-二氯乙酸盐、三氟 乙酸盐、丙酸盐、己酸盐、辛酸盐、癸酸盐、十一碳烯酸盐、乙醇酸盐、葡糖酸盐、乳酸盐、癸二酸盐、己二酸盐、戊二酸盐、丙二酸盐、草酸盐、马来酸盐、琥珀酸盐、富马酸盐、洒石酸盐、柠檬酸盐、棕榈酸盐、硬脂酸盐、油酸盐、肉桂酸盐、月桂酸盐、苹果酸盐、谷氨酸盐、焦谷氨酸盐、天冬氨酸盐、苯甲酸盐、甲磺酸盐、苯磺酸盐、对甲苯磺酸盐、海藻酸盐、抗坏血酸盐、水杨酸盐、4-氨基水杨酸盐、萘二磺酸盐等。这些盐可通过本专业已知的方法制备。
“药学上可接受的碱加成盐”是指能够保持游离酸的生物有效性而无其它副作用的与无机碱或有机碱所形成的盐。衍生自无机碱的盐包括但不限于钠盐、钾盐、锂盐、铵盐、钙盐、镁盐、铁盐、锌盐、铜盐、锰盐、铝盐等。优选的无机盐为铵盐、钠盐、钾盐、钙盐及镁盐。衍生自有机碱的盐包括但不限于以下的盐:伯胺类、仲胺类及叔胺类，被取代的胺类，包括天然的被取代胺类、环状胺类及碱性离子交换树脂，例如氨、异丙胺、三甲胺、二乙胺、三乙胺、三丙胺、乙醇胺、二乙醇胺、三乙醇胺、二甲基乙醇胺、2-二甲氨基乙醇、2-二乙氨基乙醇、二环己胺、赖氨酸、精氨酸、组氨酸、咖啡因、普鲁卡因、胆碱、甜菜碱、乙二胺、葡萄糖胺甲基葡萄糖胺、可可碱、嘌呤、哌嗪、哌啶、N-乙基哌啶、聚胺树脂等。优选的有机碱包括异大胺二乙胺、乙醇胺、三甲胺、二环己基胺、胆碱及咖啡因。这些盐可通过本专业已知的方法制备。
本发明还包括上述化合物的前药，在本申请中，术语“前药”表示可在生理学条件下或通过溶剂分解而被转化成本发明的生物活性化合物的化合物。因此，术语“前药”是指本发明的化合物的药学上可接受的代谢前体。当被给予有需要的个体时，前药可以不具有活性，但在体内被转化成本发明的活性化合物。前药通常在体内迅速转化，而产生本发明的母体化合物，例如通过在血液中水解来实现。前药化合物通常在哺乳动物生物体内提供溶解度、组织相容性或缓释的优点。具体的前药制备方法可参照Saulnier,M.G.,et al.,Bioorg.Med.Chem.Lett.1994,4,1985-1990；Greenwald,R.B.,et al.,J.Med.Chem.2000,43,475。
本文所用术语“药学上可接受的”是指不影响本发明化合物的生物活性或性质的物质(如载体或稀释剂)，并目相对无毒，即该物质可施用于个体而不造成不良的生物反应或以不良方式与组合物中包含的任意组分相互作用。
本文所用的术语“治疗”和其它类似的同义词包括以下含义:
(i)预防疾病或病症在哺乳动物中出现，特别是当这类哺乳动物易患有该疾病或病症，但尚未被诊断为已患有该疾病或病症时；
(ii)抑制疾病或病症，即遏制其发展；
(iii)缓解疾病或病症，即，使该疾病或病症的状态消退；或者
(iv)减轻该疾病或病症所造成的症状。
附图说明
图1为化合物K18对ICR小鼠体重的影响；(A)单次给药实验；(B)多次给药实验。
图2为溶媒组与经化合物K18多次给药(50mg/kg)和单次给药(500mg/kg)处理后小鼠的肝、肾、心的组织病理学变化。比例尺：100μM。
具体实施例
实施例1：2-[(2,2-二甲基丙基){[4-(4-甲基哌嗪-1-基)苯基]甲基}氨基]嘧啶-4-甲腈(K1)
将化合物M1(500mg,2.47mmol)溶于8mL无水四氢呋喃中，降温至0℃，搅拌下分批加入NaH(178mg,7.41mmol)，移至室温下反应2h，搅拌下加入化合物M2(732mg,2.72mmol)，室温下反应2h。反应完毕后，加入10mL水淬灭反应，减压蒸除四氢呋喃，用水萃取两次，有机相合并，无水硫酸钠干燥。柱层析纯化(石油醚：乙酸乙酯＝20：1)后得到白色固体即为K1化合物，收率60.3％，1H NMR(400MHz,DMSO-d6)δ8.60(d,J＝4.7Hz,1H),7.12(d,J＝4.7Hz,1H),7.01(d,J＝8.1Hz,2H),6.84(d,J＝8.3Hz,2H),4.80(s,2H),3.47(s,2H),3.07(t,J＝5.0Hz,4H),2.41(t,J＝4.9Hz,4H),2.20(s,3H),0.94(s,9H)；ESI-MS m/z：379.5[M+H]+。
实施例2：2-[(2,2-二甲基丙基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈(K2)
参照实施例1的合成方法，制备中间体M4。
将中间体M4(291mg,0.81mmol)溶于1mL水和9mL DMF的混合溶液中，搅拌下依次加入苯基硼二醇(108mg,0.89mmol)，碳酸钾(223mg,1.616mmol)，抽真空，在氩气保护下升温至80℃下反应4h。反应完毕后，恢复至室温，向反应液中加入20mL水稀释，用乙酸乙酯萃取两次，有机相合并，用饱和食盐水洗两次，无水硫酸钠干燥。柱层析(石油醚：乙酸乙酯＝12:1)后得白色固体即为K2化合物，，收率54.7％，1HNMR(400MHz,DMSO-d6)δ8.65(s,1H),7.69–7.56(m,4H),7.45(q,J＝7.2Hz,2H),7.36(t,J＝6.7Hz,1H),7.30–7.15(m,3H),4.96(s,2H),3.58(s,2H),0.99(d,J＝13.6Hz,9H)；ESI-MS m/z：357.4[M+H]+。
实施例3：2-[(2,2-二甲基丙基)({4-[4-(甲基硫基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈(K3)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-甲硫基苯基硼二醇，得到白色固体即为K3化合物，收率48.6％，1HNMR(400MHz,DMSO-d6)δ8.63(s,1H),7.63–7.55(m,4H),7.35–7.30(m,2H),7.23(d,J＝7.9Hz,2H),7.17(d,J＝4.7Hz,1H),4.95(s,2H),3.58(s,2H),2.51(d,J＝1.9Hz,3H),0.97(s,9H)；ESI-MS m/z：403.4[M+H]+。
实施例4：2-[(2,2-二甲基丙基){[4-(4-氟苯基)苯基]甲基}氨基]嘧啶-4-甲腈(K4)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-氟苯基硼二醇得到白色固体即为K4化合物，收率47.1％，1H NMR(400MHz,DMSO-d6)δ8.63(s,1H),7.62(d,J＝20.0Hz,4H),7.49(s,2H),7.24(s,2H),7.17(s,1H),4.95(s,2H),3.58(s,2H),0.97(s,9H)；ESI-MS m/z：375.4[M+H]+。
实施例5：2-[(2,2-二甲基丙基){[4-(4-甲氧基苯基)苯基]甲基}氨基]嘧啶-4-甲腈(K5)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-甲氧基苯基硼二 醇得到白色固体即为K5化合物，收率44.6％，1H NMR(400MHz,DMSO-d6)δ8.63(s,1H),7.55(t,J＝8.7Hz,4H),7.20(d,J＝7.8Hz,2H),7.16(d,J＝4.7Hz,1H),7.00(d,J＝8.3Hz,2H),4.93(s,2H),3.78(s,3H),3.56(s,2H),0.97(s,9H)；ESI-MS m/z：387.4[M+H]+。
实施例6：2-[(2,2-二甲基丙基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈(K6)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-甲磺酰基苯基硼二醇得到白色固体即为K6化合物，收率53.7％，1H NMR(400MHz,DMSO-d6)δ8.62(s,1H),7.98(d,J＝8.5Hz,2H),7.90(d,J＝8.2Hz,2H),7.69(d,J＝7.9Hz,2H),7.29(d,J＝7.8Hz,2H),7.17(d,J＝4.7Hz,1H),4.97(s,2H),3.59(s,2H),3.24(s,3H),0.97(s,9H)；ESI-MS m/z：435.4[M+H]+。
实施例7：2-({[4-(5-氰基噻吩-2-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈(K7)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为5-(二羟基硼基)噻吩-2-甲腈，得白色固体即为K7化合物，收率31.7％，1HNMR(400MHz,DMSO-d6)δ8.62(s,1H),7.97(d,J＝4.0Hz,1H),7.69(d,J＝7.9Hz,2H),7.64(d,J＝4.0Hz,1H),7.25(d,J＝7.9Hz,2H),7.17(d,J＝4.7Hz,1H),4.93(s,2H),3.58(s,2H),0.96(s,9H)；ESI-MS m/z：388.4[M+H]+。
实施例8：2-({[4-(6-氯吡啶-3-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈(K8)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为(2-氯吡啶-5-基)硼二醇，得白色固体即为K8化合物，收率34.5％，1H NMR(400MHz,DMSO-d6)δ8.71(s,1H),8.63(s,1H),8.13(d,J＝8.8Hz,1H),7.68(d,J＝7.9Hz,2H),7.59(d,J＝8.4Hz,1H),7.28(d,J＝7.8Hz,2H),7.18(d,J＝4.7Hz,1H),4.96(s,2H),3.59(s,2H),0.97(s,9H)；ESI-MS m/z：392.4[M+H]+。
实施例9：2-({[4-(3,4-二氯苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈(K9)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为(1,2-二氯苯-4-基)硼二醇，得白色固体即为K9化合物，收率52.9％，1H NMR(400MHz,DMSO-d6)δ8.62(s,1H),7.89(d,J＝2.1Hz,1H),7.67(s,1H),7.65–7.61(m,3H),7.24(d,J＝ 8.0Hz,2H),7.16(d,J＝4.7Hz,1H),4.94(s,2H),3.58(s,2H),0.96(s,9H)；ESI-MS m/z：425.4[M+H]+。
实施例10：2-[(2,2-二甲基丙基){[4-(5-甲基噻吩-2-基)苯基]甲基}氨基]嘧啶-4-甲腈(K10)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为(5-甲基噻吩-2-基)硼二醇，得白色固体即为K10化合物，收率34.8％，1HNMR(400MHz,DMSO-d6)δ8.62(s,1H),7.49(d,J＝8.0Hz,2H),7.23(d,J＝3.6Hz,1H),7.19–7.12(m,3H),6.79(dd,J＝3.6,1.2Hz,1H),4.89(s,2H),3.56(s,2H),2.44(d,J＝1.1Hz,3H),0.95(s,9H)；ESI-MS m/z：377.4[M+H]+。
实施例11：4-(4-{[(4-氰基嘧啶-2-基)(2,2-二甲基丙基)氨基]甲基}苯基)苯甲酸甲酯(K11)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-(二羟基硼基)苯甲酸甲酯，得到白色固体即为K11化合物，收率44.7％，1HNMR(400MHz,DMSO-d6)δ8.63(s,1H),8.01(d,J＝8.4Hz,2H),7.79(d,J＝8.4Hz,2H),7.68(d,J＝7.9Hz,2H),7.27(d,J＝7.9Hz,2H),7.17(d,J＝4.7Hz,1H),4.96(s,2H),3.87(s,3H),3.59(s,2H),0.97(s,9H)；ESI-MS m/z：415.4[M+H]+。
实施例12：2-({[4-(4-氯-3-氟苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈(K12)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为(1-氯-2-氟苯-4-基)硼二醇，得白色固体即为K12化合物，收率51.8％，1HNMR(400MHz,DMSO-d6)δ8.62(s,1H),7.71(dd,J＝11.0,2.1Hz,1H),7.64(t,J＝8.2Hz,3H),7.52(dd,J＝8.4,2.1Hz,1H),7.25(d,J＝7.9Hz,2H),7.16(d,J＝4.7Hz,1H),4.95(s,2H),3.58(s,2H),0.96(s,9H)；ESI-MS m/z：409.4[M+H]+。
实施例13：2-[(2,2-二甲基丙基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈(K13)
参照实施例2的合成方法，其中的原料苯基硼二醇替换为4-(4-甲基-1-哌嗪基)苯基硼二醇，得白色固体即为K13化合物，收率68.7％，1HNMR(400MHz,CDCl3)δ8.42(d,J＝4.7Hz,1H),7.47(d,J＝8.1Hz,4H),7.17(s,2H),6.98(d,J＝8.8Hz,2H),6.74(d,J＝4.7Hz,1H),4.99(s,2H),3.58(s,2H),3.29–3.23(m,4H),2.59(t,J ＝5.0Hz,4H),2.36(s,3H),1.01(s,9H)；ESI-MS m/z：455.6[M+H]+。
实施例14：2-[(环己基甲基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈(K14)
参照实施例2的合成方法，得到白色固体即为K14化合物，收率53.1％，1H NMR(400MHz,DMSO-d6)δ8.65(s,1H),7.61(m,4H),7.44(m,2H),7.32(m,3H),7.15(m,1H),4.88(s,2H),3.46(m,2H),1.81(s,1H),1.62(m,5H),1.14(m,3H),0.97(m,2H)；ESI-MS m/z：383.5[M+H]+。
实施例15：2-[(环己基甲基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈(K15)
参照实施例2的合成方法，得到白色固体即为K15化合物，收率60.7％，1H NMR(400MHz,DMSO-d6)δ8.63(s,1H),7.51(dd,J＝15.1,8.1Hz,4H),7.23(d,J＝7.7Hz,2H),7.14(d,J＝4.7Hz,1H),6.99(d,J＝8.4Hz,2H),4.85(s,2H),3.16(s,4H),2.45(s,4H),2.22(s,3H),1.81(s,1H),1.62(d,J＝16.2Hz,5H),1.15(s,3H),0.97(d,J＝11.8Hz,2H)；ESI-MS m/z：481.7[M+H]+。
实施例16：2-[(环己基甲基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈(K16)
参照实施例2的合成方法，得到白色固体即为K16化合物，收率49.3％，1H NMR(400MHz,DMSO-d6)δ8.64(s,1H),7.98(d,J＝8.5Hz,2H),7.91(d,J＝8.3Hz,2H),7.70(d,J＝7.8Hz,2H),7.35(d,J＝7.9Hz,2H),7.15(d,J＝4.7Hz,1H),4.90(s,2H),3.48(d,J＝7.4Hz,2H),3.24(s,3H),1.86–1.76(m,1H),1.62(d,J＝15.1
Hz,5H),1.14(d,J＝8.0Hz,3H),0.98(d,J＝11.8Hz,2H)；ESI-MS m/z：461.6[M+H]+。
实施例17：2-(新戊基(4-(噻唑-4-基)苄基)氨基)嘧啶-4-甲腈(K17)
参照实施例2的合成方法，得到白色固体即为K17化合物，收率32.9％，1H NMR(400MHz,DMSO-d6)δ9.17(s,1H),8.62(s,1H),8.09(s,1H),7.91(s,2H),7.22(s,3H),4.93(s,2H),3.57(s,2H),0.96(s,9H)；ESI-MS m/z：364.3[M+H]+。
实施例18：2-((4-(2-(4-甲基哌嗪-1-基)噻唑-4-基)苄基)(新戊基)氨基)嘧啶-4-甲腈(K18)
参照实施例2的合成方法，得到白色固体K18化合物，收率48.1％，1H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.75(t,J＝8.6Hz,2H),7.26–7.07(m,4H),4.91(d, J＝8.2Hz,2H),3.56(s,2H),3.43(s,4H),2.42(s,4H),2.22(s,3H),0.95(s,9H)；ESI-MS m/z：462.6[M+H]+。
实施例19(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺(K19)
称取化合物1(530mg,2.34mmol)和化合物2(300mg,1.95mmol)置于100mL茄形瓶，加25mL DMF溶解，室温搅拌12h。反应结束后，DCM稀释反应液，10％盐酸洗涤，无水硫酸钠干燥后进行柱层析分离(二氯甲烷：甲醇＝50：1)，得黄白色固体，即中间体3。
称取中间体3(100mg,0.29mmol)和HATU(121mg,0.32mmol)置入25mL茄形瓶中，加入10mL乙腈，加入DIPEA(191μL,1.16mmol)和化合物4(33mg,0.32mmol)反应10min。反应结束进行干燥，柱层析纯化(二氯甲烷：甲醇＝50：1)，得黄白色固体，即中间体5。
中间体5置于25mL二颈瓶中，N2保护，加入7mL无水DCM与DIPEA(386μL,0.92mmol)溶解，置于低温冷阱中冷却至-15℃；另称取三氧化硫吡啶(146mg,0.88mmol)溶于1mL无水DMSO形成混合液，加入-15℃的二颈瓶反应液中，低温反应1h。反应结束进行干燥，柱层析纯化(石油醚：乙酸乙酯：甲醇＝16：4：1)得白色固体产物即化合物K19，收率68％。其M.P.146-148℃,其1H NMR(400MHz,DMSO-d6)δ10.98(s,1H),7.75(dd,J＝16.0,8.3Hz,1H),7.39–7.09(m,2H),6.85(dtd,J＝9.1,6.1,2.9Hz,1H),4.84–4.32(m,2H),4.14–3.73(m,3H),3.12– 2.89(m,2H),2.86–2.63(m,2H),2.18(dt,J＝17.4,7.6Hz,1H),1.97–1.54(m,7H),1.53–1.07(m,6H)；13C NMR(101MHz,DMSO)δ215.55,175.04,173.87,170.82,158.33,156.03,135.42,132.87,126.01,112.14,108.84,106.89,103.17,102.58,60.23,56.09,49.07,46.42,43.18,42.55,41.83,41.43,39.37,35.69,30.44,29.57,29.16,25.70,24.61,23.49,21.22,18.18,14.55；MS(ESI):426.4[M+H]+。
实施例20(1R，2R)-2-(2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K20)
该实施例的制备方法参考实施例19的制备步骤，2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-鎓替代化合物1，最终得白色固体即化合物K20，收率71％。其M.P.137-140℃；其1H NMR(400MHz,DMSO-d6)δ10.88(s,1H),8.30–8.01(m,1H),7.48(d,J＝7.6Hz,0H),7.38(d,J＝7.7Hz,1H),7.32–7.24(m,1H),7.08–6.91(m,2H),4.78–4.46(m,2H),4.26–3.52(m,7H),3.09–2.81(m,2H),2.74–2.54(m,2H),1.86–1.61(m,4H),1.40–1.14(m,4H)；13C NMR(101MHz,CDCl3)δ211.38,211.31,175.85,175.79,174.54,174.16,136.00,131.28,125.61,121.72,119.67,117.50,110.85,106.62,70.07,69.90,69.71,69.49,54.76,54.69,46.33,46.17,43.39,42.96,40.07,39.87,29.27,28.86,25.27,24.49,23.29；MS(ESI):410.4[M+H]+。
实施例21(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺(K21)
该实施例的制备方法参考实施例19的制备步骤，其中化合物6替代化合物4， 得白色固体产物即化合物K21，收率67％。其1H NMR(400MHz,DMSO)δ11.01(s,1H),8.15–8.02(m,1H),7.32–7.14(m,2H),6.86(tdd,J＝9.2,4.8,2.6Hz,1H),4.74–4.42(m,2H),4.34–3.38(m,7H),3.05–2.53(m,4H),1.92–1.57(m,4H),1.36–1.23(m,4H).
实施例22(1R，2R)-2-(6，8-二氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺(K22)
该实施例的制备方法参考实施例19的制备步骤，得白色固体产物即化合物K22，收率66％。其1HNMR(400MHz,DMSO)δ11.48(s,1H),8.30–8.02(m,1H),7.21–7.05(m,1H),6.88(d,J＝12.6Hz,1H),4.70(q,J＝13.9Hz,2H),4.51–3.36(m,7H),3.06–2.86(m,2H),2.74–2.57(m,2H),1.71–1.27(m,8H)。
实施例23(1R,2R)-2-(8-氯-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺(K23)
该实施例的制备方法参考实施例19的制备步骤，得白色固体产物即化合物K23，收率65％。其1H NMR(400MHz,DMSO)δ11.12(d,J＝4.3Hz,1H),8.30–8.05(m,1H),7.63–7.42(m,1H),7.30(dd,J＝8.6,1.9Hz,1H),7.03(ddt,J＝7.9,3.6,1.9Hz,1H),4.78–4.49(m,2H),4.48–3.39(m,7H),3.07–2.82(m,2H),2.79–2.57(m,2H),1.86–1.11(m,8H)。
实施例24(1R,2R)-2-(8-溴-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺(K24)
该实施例的制备方法参考实施例19的制备步骤，得黄白色固体即化合物K24，收率69％。其1H NMR(400MHz,DMSO)δ11.14(d,J＝5.1Hz,1H),8.38–7.94(m,1H),7.80–7.51(m,1H),7.38–7.05(m,3H),4.88–4.43(m,2H),4.35–3.45(m,7H),3.20–2.86(m,2H),2.87–2.58(m,2H),1.83–1.66(m,4H),1.36–1.19(m,4H)。
实施例25(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K25)
该实施例的制备方法参考实施例19的制备步骤，得白色固体产物即化合物K25，收率40％。其1HNMR(300MHz,DMSO)δ11.49(s,1H),8.32–8.05(m,1H),7.57–7.39(m,1H),7.04(d,J＝5.4Hz,2H),4.83–4.55(m,2H),4.40–3.44(m, 7H),3.06–2.82(m,2H),2.78–2.54(m,2H),1.81(d,J＝15.7Hz,4H),1.26(d,J＝12.3Hz,4H)。
实施例26(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K26)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K26，收率42％。其1HNMR(300MHz,DMSO)δ11.49(s,1H),8.29–8.03(m,1H),7.56–7.39(m,1H),7.04(d,J＝5.3Hz,2H),4.82–4.64(m,2H),4.57–3.39(m,7H),3.07–2.89(m,2H),2.78–2.54(m,2H),1.72(s,4H),1.33–1.23(m,4H)。
实施例27(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K27)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K27，收率66％。其1HNMR(400MHz,DMSO)δ11.48(s,1H),8.30–8.05(m,1H),7.56–7.41(m,1H),7.04(d,J＝6.5Hz,2H),4.80–4.54(m,2H),4.54–3.38(m,7H),3.06–2.53(m,4H),1.91–1.25(m,8H)。
实施例28(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K28)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K28，收率51％。其1HNMR(400MHz,DMSO)δ11.37(s,1H),8.34–8.04(m,1H),7.38–7.20(m,1H),6.96–6.88(m,2H),4.78–4.52(m,2H),4.51–3.44(m,7H),3.08–2.90(m,2H),2.81–2.57(m,2H),1.73(m,4H),1.25(m,4H)。
实施例29(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K29)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K29，收率63％。其1H NMR(400MHz,DMSO)δ10.96(d,J＝4.1Hz,1H),8.31–7.99(m,1H),7.12–6.83(m,2H),6.63(dd,J＝7.6,5.7Hz,1H),4.77–4.40(m,2H),4.37–3.92(m,3H),3.89(s,3H),3.87–3.42(m,4H),3.04–2.54(m,5H),1.91–1.61(m,5H),1.35–1.13(m,4H)。
实施例30(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K30)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K30，收率43％。其1HNMR(300MHz,DMSO)δ10.96(s,1H),8.33–8.02(m,1H),7.15–6.83(m,2H),6.63(dd,J＝7.7,4.2Hz,1H),4.74–4.50(m,2H),4.49–3.88(m,7H),3.87–3.38(m,3H),3.13–2.76(m,2H),2.75–2.54(m,2H),1.91–1.72(m,4H),1.30(m,4H)。
实施例31(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K31)
该实施例的制备方法参考实施例19的制备步骤，得白色固体产物即化合物K31，收率68％。其1H NMR(400MHz,DMSO)δ11.07(d,J＝3.9Hz,1H),8.30–8.02(m,1H),6.94–6.72(m,1H),6.56(ddt,J＝11.5,3.9,2.0Hz,1H),4.78–4.46(m,2H),4.45–3.88(m,7H),3.87–3.46(s,3H),3.16–2.52(m,4H),2.05–1.45(m,4H),1.44–1.09(m,4H)。
实施例32(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺(K32)
该实施例的制备方法参考实施例19的制备步骤，得白色固体即化合物K32，收率58％。其1HNMR(400MHz,DMSO)δ11.07(s,1H),8.30–8.03(m,1H),6.91–6.75(m,1H),6.60–6.52(m,1H),4.71–4.45(m,2H),4.45–3.88(m,7H),3.87–3.44(s,3H),3.04–2.75(m,2H),2.70–2.54(m,2H),1.82–1.26(m,8H)。
实施例33 2-((4-氯苄基)(新戊基)氨基)嘧啶-4-甲腈(K33)
该实施例的制备方法参考实施例1的制备步骤，以4-氯溴苄为原料，得到白色固体产物，收率55％。1H NMR(400MHz,DMSO-d6)δ8.62(s,1H),7.36(d,J＝8.4Hz,2H),7.21–7.15(m,3H),4.88(s,2H),3.56(s,2H),0.95(s,9H).13C NMR(101MHz,CDCl3)δ162.69,159.34,141.29,136.28,132.79,128.68,128.36,116.23,112.24,57.96,51.89,34.75,28.64.HRMS(ESI)for C17H19ClN4[M+H]+:calcd,315.1371；found,315.1370.
实施例34 2-((4-溴苄基)(新戊基)氨基)嘧啶-4-甲腈(K34)
该实施例的制备方法参考实施例1的制备步骤，以4-溴溴苄为原料，得到白色固体产物，收率55％。1H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.48(d,J＝8.2Hz,2H),7.17(d,J＝4.7Hz,1H),7.11(d,J＝8.0Hz,2H),4.85(s,2H),3.55(s, 2H),0.94(s,9H).13C NMR(75MHz,CDCl3)δ162.68,159.35,141.29,136.82,131.63,128.84,120.85,116.23,112.26,57.98,51.96,34.75,28.63.HRMS(ESI)for C17H19BrN4[M+H]+:calcd,359.0866；found,359.0865.
实施例35 2-((萘-2-基甲基)(新戊基)氨基)嘧啶-4-甲腈(K35)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率50％。1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),7.89–7.80(m,3H),7.62(s,1H),7.51–7.44(m,2H),7.34(d,J＝8.5Hz,1H),7.17(d,J＝4.7Hz,1H),5.08(s,2H),3.63(s,2H),0.98(s,9H).13C NMR(101MHz,CDCl3)δ162.90,159.35,141.32,135.21,133.33,132.64,128.40,127.70,126.19,125.72,125.29,116.33,112.11,57.91,52.50,34.81,28.71.HRMS(ESI)for C21H22N4[M+H]+:calcd,331.1917；found,331.1919.
实施例36 2-(新戊基(喹啉-2-基甲基)氨基)嘧啶-4-甲腈(K36)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率27％。1HNMR(300MHz,DMSO-d6)δ8.75–8.44(m,1H),8.28(d,J＝8.6Hz,1H),7.94–7.86(m,2H),7.77–7.66(m,1H),7.60–7.50(m,1H),7.31(d,J＝8.6Hz,1H),7.15(d,J＝4.7Hz,1H),5.12(s,2H),3.71(s,2H),0.99(s,9H).13C NMR(101MHz,CDCl3)δ162.93,159.29,158.69,147.93,141.24,136.59,129.57,129.02,127.59,127.21,126.15,118.62,116.28,112.29,59.41,55.82,34.71,28.58.HRMS(ESI)for C20H21N5[M+H]+:calcd,332.1870；found,332.1880.
实施例37 2-(((4’-(4-(2-羟乙基)哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈(K37)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率53％。1H NMR(400MHz,CDCl3)δ8.45(d,J＝4.7Hz,1H),7.56–7.45(m,4H),7.20(s,2H),7.00(d,J＝8.8Hz,2H),6.77(d,J＝4.7Hz,1H),5.02(s,2H),3.75(t,J＝5.3Hz,2H),3.60(s,2H),3.38–3.27(m,4H),3.13(q,J＝7.4Hz,2H),2.86–2.77(m,4H),2.72(t,J＝5.3Hz,2H),1.03(s,9H).13C NMR(101MHz,CDCl3)δ162.87,159.34,150.14,141.26,139.61,135.89,132.25,127.67,127.30,126.64,116.33,116.29,112.03,77.39,59.58,57.57,52.90,52.03,48.64,45.91,34.76,28.68.HRMS(ESI)for C29H36N6O[M+H]+:calcd,485.3023；found,485.3013.
实施例38 2-(((4’-(4-羟基哌啶-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈(K38)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率为46％。1HNMR(300MHz,DMSO-d6)δ8.63(s,1H),7.56–7.43(m,4H),7.23–7.13(m,3H),7.03–6.93(m,2H),4.93(s,2H),4.71(d,J＝4.2Hz,1H),3.69–3.50(m,5H),2.95–2.81(m,2H),1.87–1.74(m,2H),1.54–1.39(m,2H),0.97(s,9H).13C NMR(101MHz,CDCl3)δ162.88,159.33,150.43,141.28,139.75,135.74,131.56,127.62,127.29,126.59,116.51,116.34,112.02,67.88,57.70,52.03,47.07,34.77,34.09,28.69.HRMS(ESI)for C28H33N5O[M+H]+:calcd,456.2758；found,456.2747.
实施例39 2-(((2-甲基-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈(K39)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率为54％。1H NMR(300MHz,CDCl3)δ8.46(d,J＝4.7Hz,1H),7.23(d,J＝8.7Hz,2H),7.18–7.13(m,1H),6.98(d,J＝8.7Hz,4H),6.77(d,J＝4.7Hz,1H),5.00(s,2H),3.61(s,2H),3.35–3.25(m,4H),2.63(t,J＝5.0Hz,4H),2.40(s,3H),2.27(s,3H),1.03(s,9H).13C NMR(101MHz,CDCl3)δ162.91,159.20,149.88,141.20,140.52,136.01,135.74,132.76,130.05,129.97,128.62,124.12,116.35,115.39,111.97,57.80,55.15,51.90,48.85,46.13,34.78,28.71,20.74.HRMS(ESI)for C29H36N6[M+H]+:calcd,469.3074；found,469.3064.
实施例40 2-(((2-氯-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈(K40)
该实施例的制备方法参考实施例1的制备步骤，得到白色固体产物，收率为51％。1H NMR(300MHz,CDCl3)δ8.46(s,1H),7.36(d,J＝8.2Hz,2H),7.28–7.19(m,2H),7.12–6.93(m,3H),6.80(d,J＝4.6Hz,1H),4.98(s,2H),3.61(s,2H),3.31(s,4H),2.62(s,4H),2.39(s,3H),1.03(s,9H).HRMS(ESI)for C28H33ClN6[M+H]+:calcd,489.2528；found,489.2519.
实施例41 2-(新戊基(4-(4-(2-氧丙基)哌嗪-1-基)苄基)氨基)嘧啶-4-甲腈(K41)
参考实施例1的制备步骤，得到K41-1白色固体产物，收率为64％。1H NMR(400MHz,DMSO-d6)δ8.63(d,J＝4.7Hz,1H),7.11(d,J＝4.7Hz,1H),7.04(d,J＝8.1Hz,2H),6.91(d,J＝8.1Hz,2H),4.81(s,2H),3.44(s,2H),3.37(t,J＝4.9Hz,4H),3.14–3.04(m,4H),1.42(s,9H),0.94(s,9H).
将中间体K41-1(330mg,1.41mg)加入10mL冷的4N的盐酸/二氧六环溶液中，置于冰浴下反应30分钟。TLC检测反应结束后，减压蒸除反应液，并加入少量甲苯，直至将反应液除尽。随后将残余物溶解于10mLDMF中，依次加入碳酸钾(487mg,3.53mmol)和氯丙酮(195mg,2.11mmol)，将反应液升温至80℃下保温反应2小时。TLC检测反应结束后，冷却至室温。向反应液中加入20mL水，用乙酸乙酯萃取(20mL×3)，有机相合并后依次用稀盐酸(10mL×2)和饱和氯化钠溶液(20mL×2)洗涤，后用无水硫酸钠干燥4小时。抽滤，将滤液减压浓缩后，进行柱层析纯化(石油醚：乙酸乙酯＝1:1)，得到K41淡黄色固体249mg，两步总收率为42％。1H NMR(400MHz,DMSO-d6)δ8.61(d,J＝4.7Hz,1H),7.13(dd,J＝4.7,1.6Hz,1H),7.02(d,J＝8.4Hz,2H),6.85(d,J＝8.3Hz,2H),4.81(s,2H),3.52(s,2H),3.28–3.21(m,2H),3.16–3.03(m,4H),2.59–2.52(m,4H),2.16–2.02(m,3H),0.95(s,9H).HRMS(ESI)for C24H32N6O[M+H]+:calcd,421.2710；found,421.2704.
实施例42 2-(异丁基((4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)甲基)氨基)嘧啶-4-甲腈(K42)
参考实施例1的制备步骤，得到白色固体产物，收率为46％。1H NMR(300MHz,DMSO-d6)δ8.66(s,1H),7.59–7.46(m,4H),7.25(d,J＝7.9Hz,2H),7.17(d,J＝4.6Hz,1H),7.00(d,J＝8.6Hz,2H),4.88(s,2H),3.47–3.40(m,2H),3.23–3.12(m,4H),2.49–2.42(m,4H),2.23(s,3H),2.19–2.08(m,1H),0.88(d,J＝6.6Hz,6H).13C NMR(101MHz,CDCl3)δ162.18,159.56,150.53,141.56,139.92,135.68,131.81,127.95,127.65,126.64,116.40,116.05,111.87,55.10,54.33,50.61,48.86,46.20,26.78,20.24.HRMS(ESI)for C27H32N6[M+H]+:calcd,441.2761； found,441.2753.
实施例43 N-(4-((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)苯基)-2-(4-甲基哌嗪-1-基)乙酰胺(K43)
参考实施例1的制备步骤，得到白色固体产物，收率为43％。1H NMR(300MHz,CDCl3)δ9.09(s,1H),8.43(d,J＝4.7Hz,1H),7.50(d,J＝8.5Hz,2H),7.22–7.08(m,2H),6.76(d,J＝4.7Hz,1H),4.94(s,2H),3.56(s,2H),3.15(s,2H),2.79–2.41(m,8H),2.36(s,3H),1.01(s,9H).13C NMR(101MHz,CDCl3)δ168.12,162.76,159.26,141.22,136.45,133.68,127.80,119.67,116.29,112.03,61.72,57.71,54.99,52.95,51.98,45.63,34.72,28.64.HRMS(ESI)for C24H33N7O[M+H]+:calcd,436.2819；found,436.2811.
实施例44 2-((4-(4-甲基哌嗪-1-羰基)苄基)(新戊基)氨基)嘧啶-4-甲腈(K44)
中间体K44-1溶于10mL乙腈中，加入DIPEA(2.13g,16.48mmol)后，将反应液升温至80℃下保温反应16小时。TLC检测反应结束后，冷却至室温。向反应液中加入20mL水，用乙酸乙酯萃取(20mL×3)，有机相合并后依次用稀盐酸(10mL×2)和饱和氯化钠溶液(20mL×2)洗涤，后用无水硫酸钠干燥4小时。抽滤，将滤液减压浓缩后，进行柱层析纯化(石油醚：乙酸乙酯＝12:1)，得到K44-2白色固体，收率为55％。1H NMR(300MHz,DMSO-d6)δ8.59(s,1H),7.89(d,J＝8.2Hz,2H),7.28(d,J＝8.0Hz,2H),7.18(d,J＝4.7Hz,1H),4.96(s,2H),3.83(s,3H),3.60(s,2H),0.96(s,9H).
将中间体K44-2(700mg,2.07mmol)加入到8mL甲醇和水的混合溶液(3：1)中，随后加入氢氧化锂(99mg,4.14mmol)，然后于冰浴下反应4小时。TLC检测反应结束后，浓缩反应液，随后在冰浴下用1N的盐酸溶液调节pH至2左右，产生大量白色固体，抽滤，用乙酸乙酯和少量乙醇洗涤滤饼，并于真空环境干燥过夜，得到粗品羧酸产物，直接用于下一步反应。将得到的羧酸加入到10mL无水四氢呋喃中，依次加入HATU(787mg,2.07mmol)、三乙胺(524mg,5.18mmol)和N-甲基哌嗪(249mg,2.48mmol)，在室温下反应2小时。TLC检 测反应结束后，用40mL乙酸乙酯稀释反应液，依次用饱和碳酸钠溶液(15mL×2)、稀盐酸溶液(15mL×2)和饱和氯化钠溶液(15mL×2)洗涤，后用无水硫酸钠干燥4小时。抽滤，将滤液减压浓缩后，进行柱层析纯化(石油醚：乙酸乙酯＝1:2)，得到化合物K44的白色固体480mg，两步收率为57％。1H NMR(300MHz,CDCl3)δ8.44(s,1H),7.35(d,J＝7.8Hz,2H),7.18(d,J＝7.8Hz,2H),6.79(d,J＝4.7Hz,1H),4.99(s,2H),3.83(s,2H),3.57(s,4H),2.37(s,7H),1.01(s,9H).13C NMR(101MHz,CDCl3)δ170.13,162.74,159.36,141.25,139.65,134.38,127.39,127.24,126.98,116.22,112.25,58.07,55.16,54.67,52.19,47.50,45.91,41.93,34.71,28.62.HRMS(ESI)for C23H30N6O[M+H]+:calcd,407.2554；found,407.2547.
实施例45 4-(((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)-N-(2-(4-甲基哌嗪-1-基)-2-氧乙基)苯甲酰胺(K45)
参考实施例44的制备步骤，得到白色固体产物，收率为34％。1H NMR(300MHz,DMSO-d6)δ8.72–8.47(m,2H),7.77(d,J＝8.0Hz,2H),7.23(d,J＝8.0Hz,2H),7.18(d,J＝4.7Hz,1H),4.94(s,2H),3.59(s,2H),3.18–3.02(m,6H),2.95–2.80(m,2H),2.70(s,3H),1.89–1.69(m,3H),0.96(s,9H).13C NMR(101MHz,CDCl3)δ167.71,162.65,159.41,141.54,141.10,132.81,127.62,126.93,116.25,112.29,58.21,54.59,52.36,45.88,44.51,43.65,34.67,33.18,28.56,27.22.HRMS(ESI)for C25H34N6O[M+H]+:calcd,435.2867；found,435.2859.
实施例46化合物对Cat K酶的抑制效果
试剂信息：Cat K抑制剂筛选试剂盒：批号，6L23K01500；供应商，BiVision。药物制备：化合物用DMSO溶解，配制成10mM储备液。使用时用Buffer配制成所需浓度。
以Ref-03作为对比化合物，结构式如下：
实验方法
1.药物初筛
组织蛋白酶K(CTSK，EC 3.4.22.38)是一种溶酶体半胱氨酸蛋白酶，参与破骨细胞骨重塑和再吸收，还能降解胶原蛋白、明胶和弹性蛋白。Biovision的组织蛋白酶K抑制剂筛选试剂盒利用活性组织蛋白酶K切割合成的基于AFC的肽底物以释放AFC的能力，可使用荧光计或荧光微孔板读取器轻松量化AFC。在存在组织蛋白酶K特异性抑制剂的情况下，该底物的裂解减少/消除，导致AFC荧光减少或完全丧失。这种简单且高通量的适应性分析试剂盒可用于筛选/研究/表征组织蛋白酶K的潜在抑制剂。

在96孔板中分别加入20μL的buffer、Cat K抑制剂、待测化合物(1μM、10μM)分别作为EC孔、IC孔、S孔；所有孔分别加入50μL的Cat K Enzyme Solution，室温孵育10-15min，以建立酶抑制剂复合物；所有孔加入30μL的Cat K Substrate Solution，室温孵育30-60min；反应的最终体积为100μL。在30-60min，选择两个时间点T1、T2检测荧光吸收值(Ex/Em＝400/505nm)，荧光吸收值记为RFU1、RFU2，并计算待测化合物对Cat K酶的抑制率(％)。
斜率＝(RFU2-RFU1)/(T2-T1)
抑制率(％)＝(EC斜率–S斜率)/EC斜率×100
2.IC50测定
筛选方法同1.1，待测化合物浓度设置在0.1nM-10μM之间，选择4-5个浓度进行检测，绘制IC50曲线，并计算IC50值。
数据处理：所有的数据用Graph pad进行统计学分析。
实验结果
结果见表1。
表1化合物IC50(nM)

注：A、B和C代表IC50值的活性范围，其中A：<10nM，B：10-100nM，C：100-500nM。
本发明化合物对Cat K酶的抑制率高，IC50数值低，对Cat K酶有很好的抑制活性。部分化合物如K13和K15的IC50值小于10nM，部分化合物如K1、K18-K22的IC50值均小于100nM，因此本发明化合物对Cat K酶具有较好的抑制作用。
实施例47化合物对Cat B酶、Cat S的抑制效果
组织蛋白酶B筛选
在96孔板中分别加入10μL的buffer、Cat B抑制剂、待测化合物(1μM、10μM)分别作为EC孔、IC孔、S孔；所有孔分别加入50μL的Cat B Enzyme Solution，室温孵育10-15min，以建立酶抑制剂复合物；所有孔加入40μL的Cat B Substrate Solution，室温孵育30-60min；反应的最终体积为100μL。在30-60min，选择两个时间点T1、T2检测荧光吸收值(Ex/Em＝400/505nm)，荧光吸收值记为RFU1、RFU2，并计算待测化合物对Cat B酶的抑制率(％)。
斜率＝(RFU2-RFU1)/(T2-T1)
抑制率(％)＝(EC斜率–S斜率)/EC斜率×100
IC50测定
筛选方法同上，待测化合物浓度设置在0.1nM-10μM之间，选择4-5个浓度进行检测，绘制IC50曲线，并计算IC50值。
数据处理：所有的数据用Graph pad进行统计学分析。
组织蛋白酶S筛选
在96孔板中分别加入10μL的buffer、Cat S抑制剂、待测化合物(1μM、10μM)分别作为EC孔、IC孔、S孔；所有孔分别加入50μL的Cat B Enzyme Solution，室温孵育10-15min，以建立酶抑制剂复合物；所有孔加入40μL的Cat S Substrate Solution，室温孵育30-60min；反应的最终体积为100μL。在30-60min，选择两个时间点T1、T2检测荧光吸收值(Ex/Em＝400/505nm)，荧光吸收值记为RFU1、RFU2，并计算待测化合物对Cat S酶的抑制率(％)。
斜率＝(RFU2-RFU1)/(T2-T1)
抑制率(％)＝(EC斜率–S斜率)/EC斜率×100
IC50测定
筛选方法同上，待测化合物浓度设置在0.1nM-10μM之间，选择4-5个浓度进行检测，绘制IC50曲线，并计算IC50值。
数据处理：所有的数据用Graph pad进行统计学分析。
化合物对Cat S和Cat B与Cat K的抑制活性的比值结果见表2。
表2部分化合物对Cat S和Cat B与Cat K的抑制活性的比值

注：“>>”表示在测试浓度下，抑制率不超过20％；“>”表示在测试浓度下，抑制率大于35％；“≈”表示在测试浓度下，抑制率约为50％；“<”表示在测试浓度下，抑制率小于50％。
上述部分化合物对Cat K表现出远超于其他两种酶1000倍的选择性，虽然在本次实验中，阳性对照Odanacatib的测试值略低于文献报道，但与之相比，本发明Cat K抑制剂仍显著提高了对Cat K的选择性，尤其是弥补了其对Cat K和Cat S选择能力的不足。
实施例48化合物对大鼠肝微粒的内在清除率和半衰期
1.配置样品溶液
取装有待测物粉末K2(分子式C23H27N3O4，4.6mg)、K3(分子式C23H26FN3O4，5.0mg)、K4(分子式C23H25F2N3O4，5.6mg)的离心管，分别加入1mL二氯甲烷溶解，超声30min，即得质量浓度为4.6mg/mL的K2贮备液，5.0mg/mL的K3贮备液，5.6mg/mL的K4贮备液，于-20℃冰箱中密封保存，备用。临用前，用甲醇逐级稀释至相应质量浓度，分别制得0.02、0.05、0.22、0.49、0.96、2.37、4.90ng/mL的K2系列标准样品工作液，0.02、0.05、0.10、0.19、1.00、2.01、4.93ng/mL的K3系列标准样品工作液，0.10、0.20、0.53、0.96、2.42、5.10、10.10ng/mL的K4系列标准样品工作液。
2.试验方法
使用移液枪取待测药物5μL,大鼠肝微粒体2μL，PBS缓冲液468μL，制成预混液，37℃水浴锅孵育5min，孵育完成后取47.5μL预混液，100μL冰冷乙腈，2.5μL的PBS缓冲液到另一新管，轻轻混匀得到对照组。在剩余预混液中加入22.5μL的NADPH溶液启动反应，轻轻吹打，立即取50μL预混液，100μL乙腈于另一新管终止反应。随后将孵育液放入水浴锅进行孵育，分别在5min、10min、20min、30min、45min、60min、90min分别取50μL加入100μL乙腈进行终止，12000r/min离心10min，取上清液上机检测。
色谱条件
色谱柱：Hypersil GOLD 100*2.1mm 3μm液相色谱柱
流动相：0.1％甲酸水溶液(A)100％乙腈(B)
梯度洗脱(0～1min：50％B，1～5min：50％B～90％B，5～7min：90％B，7～7.1min：50％B，7.1～10min：50％B)
流速：0.3ml/min柱温：40℃进样量：5μL
质谱条件
电喷雾离子源(ESI)；离子喷雾电压：4500V离子源温度：450℃气帘气压力：35psi；去簇电压均为80V。
3.标准曲线的绘制与定量下限的考察
将样品溶液在上述色谱与质谱条件进样分析，记录峰面积。以待测物质量浓度为横坐标(x)、待测物的峰面积为纵坐标(y)，采用加权法(加权系数为1/x2)进行线性回归。结果表明，K2质量浓度检测的线性范围为0.02～4.90ng/mL，定量下限为0.02ng/mL，K3质量浓度检测的线性范围为0.02～4.93ng/mL，定量下限为0.02ng/mL；K4质量浓度检测的线性范围为0.10～10.10ng/mL，定量下限为0.10ng/mL。根据结果进行统计分析，计算清除率(Clint)和半衰期(T1/2)。结果见表3。
表3化合物对大鼠肝微粒的内在清除率(Clint)和半衰期(T1/2)
注：Ref-03清除率及其半衰期数据来自文献
上述化合物与Ref-03相比，对大鼠的肝微粒的内在清除率均有所降低，其中化合物K4的清除率降低了2倍，其他化合物均小于Ref-03的250的清除率，而在半衰期方面，Ref-03的半衰期是0.6小时，本发明化合物的半衰期均大于0.6小时。因此本发明化合物的代谢稳定性更好。
实施例49化合物对破骨细胞的抑制效果
1细胞活力(毒性)检测
RAW 264.7细胞以1×105/孔的密度种于96孔板中，在含有10％FBS和1％青霉素/链霉素的DMEM培养基中培养。细胞放置于37℃、5％CO2的恒温培养 箱中培养。培养24小时后，在给药组中分别加入不同浓度的抑制剂工作液，在对照组中加入等体积的PBS工作液。继续培养2天后，去除培养上清液，PBS冲洗3遍，用CCK8细胞增殖检测试剂盒检测细胞的存活率，每孔加入100μL含CCK8的PBS，于37℃下避光孵育2小时后，用酶标仪检测450nm下的吸光度，以不含细胞和药物的培养基加入CCK8作为空白组。
存活率由以下公式计算：
细胞存活率(％)＝[(给药组吸光度平均值–空白孔吸光度平均值)/(对照组吸光度平均值–空白组吸光度平均值)]×100。
结果见表4。
表4化合物对RAW264.7细胞毒性的影响
由表5可知，RAW264.7细胞在1μM和10μM浓度的化合物K29中的细胞存活率分别为96.06％和98.89％；RAW264.7细胞在1μM和10μM浓度的化合物K31中的细胞存活率分别为85.84％和82.99％。由此可见，化合物K29在1μM和10μM浓度下对RAW264.7细胞无明显的细胞毒性，化合物K31在1μM和10μM浓度下对RAW264.7细胞有细胞毒性。
2破骨细胞分化
RAW 264.7细胞以1×105/孔的密度接种于96孔板中，在含有10％胎牛血清和1％青霉素/链霉素的DMEM培养基中培养。细胞放置于37℃、5％CO2的恒温培养箱中培养。给药组和模型组每孔加入100ng/mLRANKL诱导液培养破骨细胞，每2-3天换液(含RANKL)，第3次换液后，给药组加入不同浓度的抑制剂工作液，模型组加入等体积的PBS工作液，继续培养24h；对照组不加RANKL诱导液和抑制剂工作液，加入总体积相同的PBS工作液。去除培养上清液，PBS冲洗3遍，TRAP染色试剂盒对细胞进行染色，在光学显微镜下观察多核的破骨细胞并计数。
结果见表5。
表5化合物对RANKL诱导的RAW264.7细胞分化后的破骨细胞数量
由表5可知，与模型组相比较，1μM和10μM浓度的化合物K29和100nM和500nM浓度的K31均有抑制破骨细胞生成的趋势，其中K29在10μM浓度下明显抑制破骨细胞生成。结合表4和表5，其中化合物K29不具有细胞毒性且具有良好的抑制破骨细胞生成的作用。
实施例50体内毒性研究
实验对象为6-8周的雄性ICR小鼠，适应性饲养一周后，按照体重随机分组，随后配制不同浓度的化合物以腹腔注射(i.p)的方式分别进行单次给药和多次给药实验，并以相同组分的溶媒作为参考。
如图1所示，在单次给药剂量为500mg/kg和300mg/kg的情况下，第10天观察小鼠，均未出现死亡现象和明显的毒性反应。期间，每日对小鼠的体重进行测量，与溶媒组相比给药组的体重均未表现出显著性差异(P>0.05)。在多次给药实验中，选择50mg/kg和25mg/kg的给药剂量以每日一次的频率进行给药。连续给药一周后观察小鼠，均未出现死亡现象和明显的毒性反应。与溶媒组相比，给药组的体重均未表现出显著性差异(P>0.05)。如图2所示，分别对单次给药和多次给药最大剂量组的小鼠进行组织病理学研究，与溶媒组相比，用化合物K18处理后的小鼠未观察到明显的病理学变化。50mg/kg和25mg/kg作为安全给药剂量满足后续体内药效学研究对安全性的要求。
以上结果表明，化合物K18具有较低的体内毒性，具备一定的安全性。
实施例51抗骨质疏松体内药效实验
通过在雄性C57BL/6小鼠皮下注射地塞米松建立骨质疏松小鼠模型，模型 建立8天后，以12mg/kg、24mg/kg和36mg/kg的给药剂量对模型小鼠以腹腔注射的方式进行给药，并以Cat K抑制剂Balicatib作为阳性对照。每日一次连续给药6周后，麻醉解剖，留存血清，用ELISA方法检测血液中骨吸收生物标记物CTX的含量，并取一侧股骨，对骨密度进行测试。通过与溶媒组进行对比，评价Cat K抑制剂对骨质疏松的治疗作用。预实验效果明显。目前进入正式实验。
实施例52抗骨转移瘤体内药效实验
通过在NOD-SCID小鼠的胫骨穿刺注入C4-2B细胞建立前列腺癌骨转移模型，进一步研究本发明化合物对骨转移瘤的治疗作用。在造模4周后，以25mg/kg和50mg/kg的给药剂量对模型小鼠以腹腔注射的方式进行给药，并以常用抗骨转移药物唑来膦酸作为阳性对照。每日一次连续给药4周，期间观察记录小鼠的体重变化和瘤体体积变化。给药结束后处死小鼠，用ELISA法测试血浆中前列腺特异性抗原(prostate specific antigen,PSA)的含量，随后测试小鼠胫骨骨密度，并制作病理切片对骨组织的病理学变化进行测试。通过这些测试结果，评价Cat K抑制剂对前列腺癌骨转移瘤发展的抑制作用及对骨组织的保护作用。
测试结果初步表明，化合物K18可浓度依赖性地抑制C4-2B细胞的迁移、侵袭和粘附过程，表明Cat K抑制剂可通过影响肿瘤的转移过程有效地发挥抗肿瘤活性。
实施例53大鼠口服的绝对生物利用度实验
2.1仪器
Acquity UPLC超高效液相色谱系统(Waters公司)；TSQ Endura三重四级杆MS仪(Thermo公司)；KQ-500E型超声波清洗器(昆山市超声仪器有限公司)；3K15台式高速离心机(德国SIGMA公司)；XW-80A旋涡混合器(上海精科实业有限公司)
2.2药品与试剂
待测物：K29(分子量439.21，质量27mg)、K31(分子量457.20，质量14mg+20mg)。
试剂：HS-15为分析纯，羧甲基纤维素钠(CMC-Na)为药用级，甲酸、甲醇、乙腈均为色谱级，水为纯化水。
3试验方法
3.1色谱与质谱条件
3.1.1色谱条件
色谱柱：thermo scientific 100*2.1mm 3μm液相色谱柱
流动相：5mM乙酸铵水溶液(A)，100％乙腈(B)
梯度洗脱(0～0.5min：20％B，0.5～1.5min：20％-90％B，,1.5～4min：90％B，4～4.1min：90％-20％B，4.1-4.5min：20％B)
流速：0.25mL/min柱温：40℃进样量：2μL
3.1.2质谱条件
电喷雾离子源(ESI)；离子喷雾电压：3500V；离子源温度：300℃；辅助气：45Arb；鞘气：10Arb。
3.2给药溶液的配制
静脉腹腔给药溶液：用0.5％HS-15生理盐水溶液配制，浓度为0.2mg/mL；
灌胃给药混悬液：用0.5％CMC-Na水溶液研磨混悬，浓度为0.5mg/mL。
3.3动物给药和样品处理
3.3.1给药和采血
每化合物每种给药方式采用2只SD大鼠进行试验。
K29和K31两个化合物进行静脉注射和灌胃给药方式。静脉给药体积均为5mL/kg，分别在给药后2min、10min、30min、1h、2h、4h、7.5h、24h颈静脉采集0.2mL血液，灌胃给药组，10mL/kg，分别在给药后5min、15min、30min、1h、2h、4h、8h、24h颈静脉采集0.2mL血液，所有血液样品肝素抗凝，4000g离心10min，取上清血浆冻存待测。
3.3.2样品处理
取50μL血浆样品，加入150μL乙腈，涡旋混匀，9100g离心10min，取上清液进样2μL上机检测。
试验结果见表6-10。
表6 SD大鼠给药K29后血浆中K29的血药浓度数据(ng/mL)

表7大鼠给药K29后血浆中K29的血药浓度数据(ng/mL)
表8 SD大鼠给药K31后血浆中K31的药代动力学参数

表9 SD大鼠给药K31后血浆中K31的药代动力学参数
表10各化合物大鼠口服或腹腔注射PK试验结果总结
由表10可见，化合物K29和K31的口服生物利用度分别为62.1％和51.0％，口服生物利用度良好。

Claims (12)

  1. 一种式0化合物或其药学上可接受的盐或光学异构体，其通式结构如下所示：
    其中，X为C或N；
    R1选自H、取代或未取代的C1-10烷基、取代或未取代的C3-C10环烷基；其中，所述的取代基选自卤素、氨基、氰基、羟基、醛基、羧基、砜基；
    R*选自卤素或C1-6烷基；
    Y为环基，位于所连接芳香环的任意位置，通过1或2个碳原子与芳香环相连，任选为C3-10环烷基、C6-12芳香环、C5-12杂环；
    其中，所述的C6-12芳香环包含C6-12芳环和C6-12杂芳环；其中所述C6-12杂芳环含有至少一个杂原子；其中所述C5-12杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
    t为0或1；当t为0时，R5位于所连芳香环的任意位置；
    R5选自H、卤素、氨基、氰基、C1-10烷基、C1-10烷氧基、C3-10环烷基、取代的C3-10杂环烷基、-S(O)2R2、-C(O)R2、-NR3R4、-C(O)NHR7、-SR6、-OR6；
    其中所述C3-10杂环烷基的取代基选自羟基、C1-10烷基；
    其中，所述C1-10烷基可进一步被羟基、-C(O)R2取代；
    其中，所述R2选自H、氨基、卤素、取代或未取代的C1-6烷基、C1-6烷氧基、C3-8环烷基或C3-8杂环烷基；其中，所述C1-6烷基、C1-6烷氧基、C3-8环烷基或C3-8杂环烷基的取代基为C1-6烷基。
    其中，所述R3、R4分别独立选自H、-C(O)R8；或者R3、R4与它们相连的N共同形成至少含有一个N的4-8元环；其中，所述R8选自被哌嗪基或甲基哌嗪取代的C1-6烷基
    其中，所述R6选自C1-6烷基；
    其中，所述R7选自C1-6烷基，其中C1-6烷基可进一步被-C(O)R9取代；其中R9选自哌嗪基或甲基哌嗪基；
    其中，所述C3-10杂环烷基或C3-8杂环烷基含有1-3个杂原子，所述杂原 子任选O、N或S；
    其中，所述卤素为单取代或者多取代，选自F、Cl、Br、I。
  2. 一种式I或式II化合物或其药学上可接受的盐或光学异构体，其通式结构如下所示：
    其中：式I中，X为C或N；
    R1选自H、取代或未取代的C1-10烷基、取代或未取代的C3-C10环烷基；其中，所述的取代基选自卤素、氨基、氰基、羟基、醛基、羧基、砜基；
    Y为环基，位于所连接芳香环的任意位置，任选为C3-10环烷基、C6-12芳香环、C5-12杂环；
    其中，所述的C6-12芳香环包含C6-12芳环和C6-12杂芳环；其中所述C6-12杂芳环含有至少一个杂原子；其中所述C5-12杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
    R5选自H、卤素、氨基、氰基、C1-10烷基、C1-10烷氧基、C3-10环烷基、-S(O)2R2、-C(O)R2、-NR3R4、-SR6、-OR6；其中，所述R2选自H、氨基、卤素、C1-6烷基、C1-6烷氧基、C3-8环烷基；其中，所述R3、R4与它们相连的N共同形成至少含有一个N的4-8元环；其中所述R6选自C1-6烷基；
    其中，所述卤素为单取代或者多取代，选自F、Cl、Br、I；
    式II中，R1、R2各自独立选自H、卤素、氰基、氨基、取代或非取代的C1-6烷基、取代或非取代的C1-6烷氧基，所述取代的C1-6烷基或C1-6烷氧基进一步的被至少一个卤素或羟基取代；式II中的t为化学键，任选中至少一种。
  3. 如权利要求2所述的化合物或其药学上可接受的盐或光学异构体，其特征在于，其中，式I中，
    X为C或N；
    R1选自C1-10烷基、C3-C10环烷基；
    Y为环基，任选为C3-10环烷基、C6-12芳香环、C5-12杂环；
    其中，所述的C6-12芳香环包含C6-12芳环和C6-12杂芳环；其中所述C6-12杂芳环含有至少一个杂原子；其中所述C5-12杂环为饱和杂环或不饱和杂环，杂环含有1-3个杂原子；其中所述杂原子任选O、N或S；
    R5选自H、卤素、氨基、氰基、C1-10烷基、C1-10烷氧基、C3-10环烷基、-S(O)2R2、-C(O)2R2、-NR3R4、-SR6、-OR6；其中，所述R2选自H、氨基、卤素、C1-6烷基、C1-6烷氧基、C3-8环烷基；其中，所述R3、R4与它们相连的N共同形成至少含有一个N的4-8元环；其中所述R6选自C1-6烷基；
    其中，所述卤素为单取代或者多取代，选自F、Cl、Br、I；
    式I中，R1、R2各自独立选自H、卤素、取代或非取代的C1-3烷基、取代或非取代的C1-3烷氧基，所述取代的C1-3烷基或C1-3烷氧基进一步的被至少一个F取代。。
  4. 一种如权利要求2所述的化合物或其药学上可接受的盐或光学异构体，其特征在于，Y选自以下基团：式I中，苯基、吡啶基、噻吩基、噻唑基；式II中，R1、R2各自独立选自H、F、Cl、Br、甲基、甲氧基、三氟甲氧基。
  5. 一种如权利要求2所述的化合物或其药学上可接受的盐或光学异构体，其特征在于，式I中，R5选自H、F、Cl、氰基、甲基、甲硫基、甲氧基、甲砜基、甲羰基、甲基哌嗪基；式II中，R1、R2各自独立选自H和F。
  6. 一种式0或式II化合物或其药学上可接受的盐或光学异构体，其特征在于，其具体选自如下化合物：
    1)2-[(2,2-二甲基丙基){[4-(4-甲基哌嗪-1-基)苯基]甲基}氨基]嘧啶-4-甲腈
    2)2-[(2,2-二甲基丙基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈
    3)2-[(2,2-二甲基丙基)({4-[4-(甲基硫基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈
    4)2-[(2,2-二甲基丙基){[4-(4-氟苯基)苯基]甲基}氨基]嘧啶-4-甲腈
    5)2-[(2,2-二甲基丙基){[4-(4-甲氧基苯基)苯基]甲基}氨基]嘧啶-4-甲腈
    6)2-[(2,2-二甲基丙基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈
    7)2-({[4-(5-氰基噻吩-2-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈
    8)2-({[4-(6-氯吡啶-3-基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈
    9)2-({[4-(3,4-二氯苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈
    10)2-[(2,2-二甲基丙基){[4-(5-甲基噻吩-2-基)苯基]甲基}氨基]嘧啶-4-甲腈
    11)4-(4-{[(4-氰基嘧啶-2-基)(2,2-二甲基丙基)氨基]甲基}苯基)苯甲酸甲酯
    12)2-({[4-(4-氯-3-氟苯基)苯基]甲基}(2,2-二甲基丙基)氨基)嘧啶-4-甲腈
    13)2-[(2,2-二甲基丙基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈
    14)2-[(环己基甲基)[(4-苯基苯基)甲基]氨基]嘧啶-4-甲腈
    15)2-[(环己基甲基)({4-[4-(4-甲基哌嗪-1-基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈
    16)2-[(环己基甲基)({4-[4-(甲基磺酰基)苯基]苯基}甲基)氨基]嘧啶-4-甲腈
    17)2-(新戊基(4-(噻唑-4-基)苄基)氨基)嘧啶-4-甲腈
    18)2-((4-(2-(4-甲基哌嗪-1-基)噻唑-4-基)苄基)(新戊基)氨基)嘧啶-4-甲腈
    19)(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
    20)(1R，2R)-2-(2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    21)(1R，2R)-2-(8-氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
    22)(1R，2R)-2-(6，8-二氟-2，3，4，9-四氢-1H-吡啶并[3，4-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
    23)(1R,2R)-2-(8-氯-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
    24)(1R,2R)-2-(8-溴-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚-2-羰基)-N-((S)-4-氧代四氢呋喃-3-基)环己烷-1-甲酰胺；
    25)(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    26)(1R，2R)-2-(6-(三氟甲氧基)-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    27)(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    28)(1R，2R)-2-(6-氟-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    29)(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    30)(1R，2R)-2-(6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    31)(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(S)-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺；
    32)(1R，2R)-2-(8-氟-6-甲氧基-2，3，4，5-四氢-1H-吡啶并[4，3-b]吲哚-2-羰基)-N-(4-氧代四氢呋喃-3-基)-环己烷-1-甲酰胺。
    33)2-((4-氯苄基)(新戊基)氨基)嘧啶-4-甲腈；
    34)2-((4-溴苄基)(新戊基)氨基)嘧啶-4-甲腈；
    35)2-((萘-2-基甲基)(新戊基)氨基)嘧啶-4-甲腈；
    36)2-(新戊基(喹啉-2-基甲基)氨基)嘧啶-4-甲腈；
    37)2-(((4’-(4-(2-羟乙基)哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
    38)2-(((4’-(4-羟基哌啶-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
    39)2-(((2-甲基-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
    40)2-(((2-氯-4’-(4-甲基哌嗪-1-基)-[1，1’-联苯基]-4-基)甲基)(新戊基)氨基)嘧啶-4-甲腈；
    41)2-(新戊基(4-(4-(2-氧丙基)哌嗪-1-基)苄基)氨基)嘧啶-4-甲腈；
    42)2-(异丁基((4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)甲基)氨基)嘧啶-4-甲腈；
    43)N-(4-((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)苯基)-2-(4-甲基哌嗪-1-基)乙酰胺；
    44)2-((4-(4-甲基哌嗪-1-羰基)苄基)(新戊基)氨基)嘧啶-4-甲腈；
    45)4-(((4-氰基嘧啶-2-基)(新戊基)氨基)甲基)-N-(2-(4-甲基哌嗪-1-基)-2-氧乙基)苯甲酰胺。
  7. 一种如权利要求2所述的式I或式II化合物的制备方法，其特征在于，式I的制备方法包括如下步骤：
    化合物T5与化合物T6反应生成式Ⅰ化合物；其中R1、R5、X、Y如权利要求1中所定义；
    和/或，式II的制备方法包括如下步骤：
    步骤1)化合物P2与4-氨基四氢呋喃-3-醇发生缩合反应；
    步骤2)步骤1所得产物经氧化剂氧化生成式ⅠI化合物。
  8. 一种如权利要求7所述的制备方法，其特征在于，其中化合物T5的制备方法如下：
    化合物T3与化合物T4反应生成化合物T5。
  9. 如权利要求7所述的方法，其特征在于，其中化合物P2的合成方法如下：
    化合物P1与(3aR,7aS)-六氢异苯并呋喃-1,3-二酮反应生成化合物P2。
  10. 一种药用组合物，包含权利要求1-6任一权利要求所述化合物或其药学上可接受的盐或其光学异构体。
  11. 一种如权利要求1-6任一权利要求所述化合物或其药学上可接受的盐或其光学异构体，在制备治疗以组织蛋白酶K为靶向的疾病的药物中的应用。
  12. 一种如权利要求11所述的应用，其特征在于，所述以组织蛋白酶K为靶向的疾病包括肿瘤、甲状腺疾病、心血管疾病、骨疾病和牙龈病；优选的，所述甲状腺疾病包括甲状腺功能亢进；优选的，所述心血管疾病包括动脉粥样硬化、心肌肥厚、心力衰竭；优选的，所述骨疾病包括骨质疏松症、骨关节炎、类风湿性关节炎；优选的，所述甲牙龈病包括牙龈炎和牙周炎；优选的，所述以组织蛋白酶K为靶向的疾病为骨质疏松症。
PCT/CN2023/073612 2022-01-21 2023-01-28 一种组织蛋白酶k抑制剂与其制备方法及其应用 WO2023138695A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202210098531.3A CN116514804A (zh) 2022-01-21 2022-01-21 一种组织蛋白酶k抑制剂与其制备方法及其应用
CN202210098531.3 2022-01-21
CN202210156862.8A CN116655540A (zh) 2022-02-21 2022-02-21 一种Cat K抑制剂与制备方法及其应用
CN202210156862.8 2022-02-21

Publications (1)

Publication Number Publication Date
WO2023138695A1 true WO2023138695A1 (zh) 2023-07-27

Family

ID=87347913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/073612 WO2023138695A1 (zh) 2022-01-21 2023-01-28 一种组织蛋白酶k抑制剂与其制备方法及其应用

Country Status (1)

Country Link
WO (1) WO2023138695A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194418A (ja) * 1992-01-23 1993-08-03 Kirin Brewery Co Ltd ２−アミノピリミジン誘導体及びその用途
CN1678613A (zh) * 2002-08-30 2005-10-05 诺瓦提斯公司 杂芳基腈衍生物
CN101687864A (zh) * 2007-06-26 2010-03-31 阿斯利康(瑞典)有限公司 作为组织蛋白酶k抑制剂的1-氰基环丙基-衍生物
CN106478564A (zh) * 2015-08-29 2017-03-08 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05194418A (ja) * 1992-01-23 1993-08-03 Kirin Brewery Co Ltd ２−アミノピリミジン誘導体及びその用途
CN1678613A (zh) * 2002-08-30 2005-10-05 诺瓦提斯公司 杂芳基腈衍生物
CN101687864A (zh) * 2007-06-26 2010-03-31 阿斯利康(瑞典)有限公司 作为组织蛋白酶k抑制剂的1-氰基环丙基-衍生物
CN106478564A (zh) * 2015-08-29 2017-03-08 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry CAS; 30 August 2016 (2016-08-30), ANONYMOUS : "4-Pyrimidinecarbonitrile, 2-[[(3-bromophenyl) methyl]methylamin o]- ", XP093080139, retrieved from STN Database accession no. 1982714-07-7 *
MILTZ, WOLFGANG ET AL.: "Design and Synthesis of Potent and Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 25, no. 16, 29 June 2017 (2017-06-29), XP085133595, DOI: 10.1016/j.bmc.2017.06.050 *
TENO, N. ; IRIE, O. ; MIYAKE, T. ; GOHDA, K. ; HORIUCHI, M. ; TADA, S. ; NONOMURA, K. ; KOMETANI, M. ; IWASAKI, G. ; BETSCHART, C.: "New chemotypes for cathepsin K inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 18, no. 8, 15 April 2008 (2008-04-15), Amsterdam NL , pages 2599 - 2603, XP022606355, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2008.03.036 *

Similar Documents

Publication Publication Date Title
EP3590924B1 (en) Novel isoindoline derivative, and pharmaceutical composition and application thereof
JP6676541B2 (ja) 置換された４−フェニルピペリジン、その調製及び使用
WO2003091256A1 (fr) Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive
EP2560655B1 (en) Substituted pyrimidines
TW200944511A (en) Substituted 4-hydroxypyrimidine-5-carboxamides
CZ294648B6 (cs) Pyridin-substituované deriváty pyrazolpyridinu, způsob jejich výroby, léčiva tyto látky obsahující a jejich použití
CN101687852A (zh) 可用作激酶抑制剂的噻唑类和吡唑类化合物
CN101951775A (zh) 四氢噻吩并吡啶
CN104109166B (zh) 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
JP4495377B2 (ja) ピラジノントロンビン阻害剤
CN111170995A (zh) Ask1抑制剂及其应用
CN112028877B (zh) 烷氧吡啶酮化合物及其制备方法和用途
WO2023138695A1 (zh) 一种组织蛋白酶k抑制剂与其制备方法及其应用
EP4039674A1 (en) Sulfo-substituted biaryl compound or salt thereof, preparation method therefor, and use thereof
WO2020244530A1 (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
CN111936470B (zh) 用作fgfr不可逆抑制剂的酰胺基吡唑类化合物
CN109776494B (zh) 一种多靶点抗肿瘤活性的烟酰胺磷酸核糖转移酶氮芥类抑制剂及其制备与应用
CN109096272B (zh) 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用
CN117105936A (zh) 一种作为FLT3抑制剂的咪唑并[1,2－a]吡啶化合物及其制备方法和用途
CN107501279A (zh) 呋喃并喹啉二酮类化合物及其医药用途
CN104418820A (zh) 作为溶血磷脂酸受体拮抗剂的羧酸衍生物
WO2020094156A1 (zh) 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
WO2022233263A1 (zh) 三并环类泛素特异性蛋白酶1抑制剂及其用途
CN113135929A (zh) 呋喃并吡啶酮酰胺化合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743009

Country of ref document: EP

Kind code of ref document: A1